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RAPID IDENTIFICATION OF NEW TRANSCRIBED HUMAN SEQUENCES: 
A SEMI-ORDERED APPROACH 
Andrew Martin Dearlove 
MRC UK Human Genome Mapping Project Resource Centre 
A thesis submitted for an M.Sc. at the University of Durham, June 1995 
The sequencing of the DNA that is actually expressed and turned into protein has many 
applications to facilitate the discovery of new human genes, mapping of the human 
genome, and identification of coding regions in genomic sequences. 
The redundancy encountered in systematic sequencing programmes necessitates the 
production of semi-ordered fragmentary cDNA libraries using various technologies, to 
subsequently generate high quality expressed sequence tags (ESTs). Modified standard 
protocols and new ideas and methodologies were utilised. 
1. Intact and biologically active pure RNA was extracted from various fetal tissues using 
further optimised purification methods including ultracentrifugation. Standard 
commercially available kits were used for mRNA purification and cDNA synthesis. 
2. A variation of the pBluescript KS I I (+/-) vector was produced to subsequendy clone 
the prepared restriction fragment sorted cDNA species. 
3. Streptavidin bead capture of PGR products, and new methods involving the use of 
helper phage, filtration, and lacZ magnetic bead purification, were used to produce 
ssDNA templates for standard automated sequencing. 
Over 75% of the cDNA fragment library clones contained inserts (average 500 bp). The 
EST data for 1167 clones (1552 sequences) showed the sorting technique subdivided the 
complex cDNA mixtures into distinct populations: sequences produced 636, 54% 
different sequence classes; and 523, 44% of the sequences were seen only once in this 
study. Database match searches identified 152 (13%) unknown ESTs, and 96 (8%) 
unique unknowns from the six different populations. No known intron or rRNA 
sequences, and only a small number of mitochondrial sequences were generated: 
suggesting the quality and integrity of the purified RNA was high. 
Combining such semi-ordered populations from different tissues significantly increases 
the complexity of a cDNA library: this strategy rapidly identifies new transcribed 
sequences and genes, to forward the Human Genome Project; aiming to map and 
sequence all of the human genome. 
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1. INTRODUCTION 
1.1. The Human Genome Project 
The Human Genome Project (HGP), mapping and sequencing the entire human genome, 
is perhaps the most exciting scientific event since the space race of the late 1960s, for 
man to walk on the moon. Around the world many hundreds of laboratories are 
analysing the genetic message encoded in DNA towards locating every gene, and 
deciphering all the instructions which specify a human being, within the next decade. 
The race is primarily against time to get a complete understanding of the role and origins 
of all genomic components, and the prospect of being able to disentangle the complex 
causes of genetic disease. The HGP is a unique initiative in biology in terms of the scale: 
sequencing the 3000 Mb human genome is a huge task, and therefore much international 
co-ordination is required. From the concept of the HGP and its early development in the 
USA it was perceived that identification of all the genes involved in diseases including 
cancer would be necessary to be able to understand and combat them, although 
knowledge of the entire genome sequence would be even more useful. 
The HGP was supported by the US Department of Energy (DOE) and the National 
Institutes of Health (NIH), and was promoted by the setting up of the Human Genome 
Organisation (HUGO) to influence and co-ordinate intemational contributions. Major 
progress depended on the co-operation and pooling of resources and the free exchange 
of data, with roles of co-ordination taken by the large scientific centres. 
The goals of the HGP have evolved with much debate as to the priorities and strategies 
to be adopted, with the ultimate goal the determination of the nucleotide sequence of the 
human genome and the genome of model organisms. The first priorities are the 
development of improved technologies for mapping and sequencing, and informatics 
systems for handling the vast amount of data that will be generated over the course of 
the project. 
Mapping the human genome provides a linear representation to describe the organisation 
of a set of landmarks, using a defined system of measurement based on co-ordinates. 
Physical maps can be cytogenetic, ordering loci by in situ hybridisation based on their 
relative position on the chromosome; or molecular, using sequence features as the 
landmarks. Genetic maps represent the genetic distance between markers: linkage maps 
base distance on centiMorgan (cM) units, a measure of the frequency of recombination 
between the specific genes. Genetic distance does not have a constant relationship with 
physical distance, because recombination frequencies vary between different regions of 
the genome. The initial phase of the HGP is focusing on establishing such physical 
(Cohen et al, 1993) and genetic maps (Weissenbach et al, 1992, NIH/GEPH 
Collaborative mapping group, 1992, and Gyapay et al., 1994), of landmarks such as 
polymorphisms, genes and specific DNA sequences. 
One strategy used in the HGP starts with the intact genome to produce long range maps 
from the maps of the DNA markers to generate cloned regions to be sequenced. The 
opposite approach is to start with the sequence from random cosmid or bacteriophage 
clones, and proceed to assemble longer range sequences by identifying overlapping sets 
of cloned sequences (contigs). 
Screening large libraries is tedious and time consuming, although multiplexing and 
simultaneous analysis techniques are amenable to automation. With the recent 
development of new vectors screening became easier, and the resolution obtained by 
genetic mapping and the maximum length of contig sequence that can be assembled 
became more compatible. Cloning technology had been limited by small cosmids that 
were able to carry exogenous DNA inserts of less than 50 kb, which was not big enough 
to contain genes from higher organisms (Little, 1992). YAC vectors which are capable 
of carrying much larger inserts of about 1 Mb, equivalent to about 1 cM on a linkage 
map was a significant development (Anand, 1992). They are not a great panacea though 
as the YAG libraries are often not ideal: showing high levels of chimaerism, there is also 
still a need to subclone into other vectors for sequencing. 
Although great advances have been made, sequencing is still a tedious and slow process: 
further increased automation (robotics) and development of alternative technologies or 
chemistries are required to dramatically improve the present speed and capacity in order 
to finish the complete sequence of the human genome to schedule by 2005. Until such 
radically different approaches that would make todays methods look primitive are 
introduced to reduce the scale of the project to a more manageable task, the question of 
what to sequence is paramount. 
The entire genome (100 Mb, 10 000-20 000 genes) of a much simpler organism, the 
microscopic nematode worm Caenorhabditis elegans is currently being sequenced 
(Sulston et al., 1992). The development and lineage of all of the worms 945 cells have 
been tracked, so the biological purpose of the 90% "junk" intron and intergenic DNA 
may become clear. Other model genomes such as Drosophila melanogaster (fruit fly). 
Arabidopsis thaliana (a simple plant) and Saccharomyces cerevisiae (yeast) are also 
being studied (Hood et al, 1992). The human genome is much greater in size (3000 
Mb) than that of these model organisms being sequenced, and so it makes sense to target 
those regions which will yield information of greatest immediate value. Indeed it is 
difficult to justify large scale blanket sequencing of the human genome at current rates 
and costs, when it could be done much quicker and cheaper in the near future. 
1.2. The value of cDNA sequencing and ESTs 
It was Sydney Brenner and Ed Southern, dominant figures in British molecular biology, 
who advised the UK Medical Research Council (MRC) that it would be expedient with 
their relatively modest resources relative to the Americans, to concentrate on analysing 
the DNA that is active: the DNA that is actually expressed and turned into protein. It is 
more cost-effective to turn to this complementary DNA or cDNA, instead of sorting 
through some 90 per cent of the "junk" DNA of the human genome. When a cell makes 
a protein, it first transcribes the relevant gene into messenger RNA, which carries the 
genetic information out of the nucleus to where the protein is made in the cytoplasm. 
The RNA is spliced, to remove the "junk" introns before protein synthesis. The cDNA is 
made from extracted mRNA using the enzyme reverse transcriptase to obtain only the 
"useful" sequence that encodes for protein. 
The main problem is one of sorting through the many types of mRNA present, accepting 
the ones desired may be less abundant than others. The efficient sequencing of human 
{Homo sapiens) cDNA clones to generate new expressed sequence tags (ESTs) with the 
minimal amount of redundancy, has therefore to be concentrated upon. An EST is 
simply part of a sequence from a cDNA that corresponds to a mRNA, and is hence by 
definition a transcribed sequence as sought after in this study. They have many 
applications including the discovery of new human genes, mapping of the human 
genome, and identification of coding regions in genomic sequences. 
1.3. Progress made using cDNAs and ESTs 
In the early 1990s when less than 200 human brain mRNAs were listed in GenBank, a 
pilot project was initiated in the USA to test the use of ESTs in a comprehensive study 
of expressed genes (Adams et al., 1991). Single-run sequence data was obtained for 
over 600 randomly chosen cDNA clones from various human brain hbraries. Double-
stranded cDNA clones in pBluescript vector were sequenced by primer (Ml3 universal 
or reverse) cycle sequencing. Double-stranded templates were produced by plasmid 
preparation (497), alkah lysis and Qiagen columns, or by the polymerase chain reaction 
(PGR), which exponentially copies and ampUfies specific nucleotide sequences between 
two convergent primers that hybridise to opposite strands (117). About 60%, 90%, and 
50% respectively, of templates produced by each method generated data. ESTs were 
examined for similarities in the GenBank nucleic acid database using BLAST (Altschul et 
al., 1990). Results showed 197 (32%) of the sequences matched to human sequences, 
repetitive elements, mitochondrial genes, ribosomal RNA genes and other nuclear genes. 
Matches to non human entries were found in 48 (8%) of the sequences, whilst 230 
(38%) had no significant matches. No inserts were found in the other 134 (22%) of 
sequences. 
It was argued ESTs can serve the same purpose as random genomic DNA sequence-
tagged-sites (STS) for the physical mapping of the human genome, whilst providing the 
additional feature of pointing direcdy to an expressed gene. PGR was used to screen a 
series of somatic cell hybrid cell lines containing defined human chromosomes or 
chromosome fragments for the presence of a given EST. Only hybrids containing the 
human gene corresponding to the EST yielded an amplified fragment, hence assigning 
the EST to a chromosome by analysis of the distribution of PGR products from hybrid 
DNA templates. It was found ESTs longer than 150 bp were most useful for mapping as 
well as the similarity searches: forty six ESTs were mapped to chromosomes. 
Sequence data was shown to be more accurate nearer the primer, decreasing rapidly 
beyond 400 bases. Average accuracy obtained for the double stranded sequencing runs 
was about 98% for up to 400 bases. ESTs submitted to GenBank (348: M61953-
M62300) were over 150 bases in length with <3% ambiguity. Overall sequence accuracy 
was over 97% based on matches to known human genes. 
Single run DNA sequencing was shown to be an efficient method of obtaining 
preliminary data on cDNA clones: enough information was obtained in 150-400 bases of 
a nucleotide sequence for early identification of the cDNA and localisation to a 
chromosome. It was shown that new sequences (230) representing previously 
uncharacterised genes could rapidly be identified. The random selection methods used 
revealed a high level of redundancy in the cDNA libraries, emphasising the importance of 
library pre-processing or normalisation techniques as the number of ESTs increases. 
A basis for the use of ESTs had been provided, demonstrating their utilisation to fast 
cDNA characterisation to help economic tagging of human genes, with the provision of 
genetic markers and a genome resource. 
The value of cDNA sequencing alongside systematic genomic sequencing was widely 
appreciated (Bergmann, 1992). The potential for rapid identification of unidentified 
genes particularly with regard to C. elegans was reviewed favourably with caution: 
suggesting that not all new cDNAs represent new proteins and genes, and that as 
databases grow, greater redundancy will be encountered. 
A representative C. elegans library, sorted by the use of negative screening, of 1517 
clones was investigated using single sequence reads (Waterston et al., 1992). A 
resultant efficient identification of about 1200 of the estimated 15 000 genes was 
obtained. Over 30% of protein sequences obtained matched those already in databases, 
providing an in vivo analysis of known genes. YACs were used to map 670 of the 
cDNAs. The C. elegans research was focused on genomic sequencing to investigate the 
purpose of all DNA as mentioned previously. 
Gene families and potential disease gene homologies between humans and C. elegans 
were identified using ESTs from a mixed stage C. elegans library (McCombie et al., 
1992). A large number (422) of new genes were again identified from only 720 ESTs, of 
which 26 were mapped. 
Large scale sequencing of cDNA using PCR amplification was used to analyse the 
quantitative and qualitative aspects of gene expression, (Okubo et al., 1991 & 1992). A 
cDNA library containing Mbo I cut (providing a constant reference point) 3' end 
fragments was constructed from the liver cancer cell line HepG2. The cDNA moieties of 
1022 randomly chosen colonies were amplified by PCR and sequenced. The average size 
of inserts was 270 bp, but inserts of less than 20 bp were found in some clones: the 
sequence similarity of the remaining 982 clones was compared with each other and 
GenBank. Over half (514, 51%) of the sequences, representing 173 different species. 
appeared more than once. The solitary sequence group consisted of 468 sequences. 
Many of the redundant group members (55 of the 514) consisted of only 3 species, 
which were identified by GenBank matches. Of the remainder of the redundant sequence 
group members, 107 (35 species) were identified and 352 (135 species) were novel. Of 
the solitary group members, 53 were identified, and 415 were novel. Hence in total from 
the 982 clones producing informative sequence 215 represented 91 known genes and 
767 clones represented 550 novel genes. It was shown there was a higher probability of 
databank matches being found with redundant sequences than solitary sequences: the 
overall chance of database matches being found with the 3' end fragments used was 
22%. The idea of "body mapping expressed genes" provided an efficient method of gene 
collection concentrating on sequencing small numbers (-1000) of cDNAs from each of 
the 200 or so different tissues of the human body, rather than normalisation or 
complexity of library. 
Single pass sequencing of 1037 human brain clones of a library pre-screened with total 
brain cDNA yielded 1024 ESTs (Khan et al., 1992): over 900 represented previously 
unidentified genes. A small subset (20) were physically mapped, assigning them to 
chromosomes by PGR amplification of human-rodent somatic cell hybrids using primers 
designed from the ESTs and analysis of the products. Hence ESTs were shown to 
potentially represent a rich source of informative gene associated polymorphic genetic 
markers. 
It was reported in early 1993 (Sikela & Auffray, 1993) that the merits of large scale 
cDNA analysis and the role of ESTs in the systematic cataloguing of genes faster than 
ever was becoming generally appreciated. It was evident from the European Community 
Symposium on Strategies in cDNA Programs (Paris, France, October 1992), that rapid 
development and expansion had occurred. Over 25 000 ESTs had by now been 
generated, with over 80% derived from human sources representing over 10000 human 
genes. Large scale cDNA approaches were being applied to many areas of research, 
with strategies adapted to suit particular interests. Tissues from many sources were 
being used in different programs. Non-normalised libraries gave information on the 
profile of the relative expression levels of active genes, whilst other pre-screened or 
normahsed libraries enriching for less common clones resulted in less redundancy. 
Clones were being sequenced from both the 5' end (more likely to yield protein 
information) and the 3' end (providing a constant reference point for comparison). PCR 
or hybridisation based strategies were being used to map the ESTs and corresponding 
genes, adding further value to them. Obviously further co-ordination of future cDNA 
projects was deemed important to reduce redundancy and optimise output. 
The partial sequence data from over 8591 human brain cDNAs was detailed by Adams et 
al., (1993), with a further 3401 ESTs from 3013 clones being described. About 6000 
distinct genes expressed in the brain were by now represented by ESTs, with over 700 
different proteins identified. A further study showed advantages of a good quality 
directionally cloned human infant brain cDNA library (Adams et al., 1993). The average 
length of these 1633 ESTs was 364 bp, and 37% of them were identified based on 
matches to over 320 different genes in the public databases. Construction of this 
directionally cloned library with size selection and improved purification methods of 
RNA led to a high coding content of the inserts of average length 1500 bp and less 
generation of non usable sequences. 
The chromosomal distribution of 320 brain expressed genes was determined by studying 
the PCR products of human-rodent somatic cell hybrids (presence of human-specific 
product), and by genetically mapping polymorphic cDNAs using the CEPH pedigrees 
and database (Polymeropoulos et al., 1993). Thence ESTs were being used further as 
gene markers on the physical map of the human gene providing a transcription map, 
suggesting a much greater future role for the polymorphic cDNAs in developing a high 
resolution genetic map. Correlation between areas of high GC content and gene density 
were noted, as was the non random distribution of genes. 
Analysis of EST data, by matching to GenBank sequences and assuming 50% EST 
redundancy, was also used to get a more accurate estimate of the number of human 
genes (Fields et al., 1994). The figure of 60 000-70 000 was consistent with others 
reached using genomic sequencing and CpG island data (Antequera & Bird, 1993): so 
was probably the most rehable to date. CpG islands are short stretches of DNA rich in 
unmethylated CpG, often marking the position of a gene, (Cross et al., 1994). 
1.4. Advances in technology 
DNA sequencing was first made possible with the discovery of restriction enzymes and 
polymerases of the 1970s. Further developments included primed synthesis and gel 
electrophoresis, but a breakthrough in the rate of sequencing was made with the advent 
of the dideoxy chain termination reaction (Sanger et al., 1977) and chemical degradation 
(Maxam & Gilbert, 1977) methods. Sequencing efficiencies were still relatively low 
though (1.5 kb per person year) due to difficulties in obtaining primers, single stranded 
templates cloned DNA and inadequate informatics. In the 1980s the introduction of 
oligonucleotide synthesisers, M13, plasmids, and computer assisted handling (Staden, 
1982) helped in these areas. By the mid eighties sequencing reaction conditions had been 
adequately optimised, and other strategies initiated including PGR (Eriich, 1989) 
sequencing. Automated fluorescent sequencing (coupling automatic gel electrophoresis, 
raw data acquisition and base calling), and robotics were also in development. 
Throughout the last decade there has been a move towards full automation with the 
objective of achieving 150 kb per person year, at a fraction of the cost. Dye primer or 
terminator chemistry is used with high quality templates, with a four label, single lane 
separation, 36 channel automated sequencer (Applied Biosystems 373A), often the 
preferred opfion (i.e. Adams et al., 1991): although other hardware is available 
(Pharmacia A.L.F.). 
The latest developments in autosequencers, data management and robotics enabled large 
throughput and analysis (i.e. Okubo et al., 1991 & 1992): and the development of 
automation to facilitate high throughput DNA sequencing was now perceived a priority 
of many laboratories (Watson et al., 1993). Both the production of good quality DNA 
templates and the sequencing process had been addressed with the objective of eventual 
integration. Developments had been made with regard to plaque or colony picking, solid 
phase recapture of purified DNA after manual centrifugation, and template sequencing 
using advanced liquid handling robots and thermal cyclers. 
A model for high-throughput automated DNA sequencing and analysis core facilities, as 
set up at The Institute for Genomic Research (TIGR) (Adams et al., 1994), was 
suggested. This system was based on automated sample preparation, template 
sequencing, and automated sequencers for data collection. Expansion had been achieved 
by evolution in DNA template production methods, sequencing chemistry. 
instrumentation, data tracking and software for sequence analysis. More sequence data 
collection was possible by increasing samples (channels/lanes) per gel, with a shorter 
electrophoresis time and longer read length. Much manual intervention was still required 
for plate preparation, clone picking, actual running of robots, data editing and quahty 
control. Integration of the data analysis and high capacity informatics was important for 
efficient feedback with regard to the earlier strategies. Balance in all areas of the project 
was required to optimise developments in each area and keep the efficiency as high as 
possible throughout. 
Combining this automated sequencing technology with randomly selected cDNA clones 
representing mRNA distributions allows construction of a detailed picture of 
transcriptional activity of a cell or tissue, including the identification of transcribed genes, 
abundance levels and degree of overlap in gene expression amongst various tissues. 
Partial cDNA sequences (ESTs) provide the fastest way to obtain gene specific data for a 
large number of independent cDNA clones. Careful Ubrary design and sequencing 
strategies maximises the amount of information that can be derived from a particular 
mRNA population. Library source and method of construction are considered to 
produce a good library where every clone sequenced has potential to be an interesting 
new gene. Sequencing redundancy can be reduced by screening with total cDNA 
(eliminating abundant clones) or subtraction/normalisation techniques (Soares et al., 
1994). Extensive facihties for accumulation and analysis of the large amount of data 
produced are required to optimise the use of the partial gene sequences. Single pass 
sequencing is often used to maximise throughput to get the largest amount of 
information per raw base sequenced. This is accurate enough for sensitive similarity 
searches, analysing a large number of independent clones to identify different gene 
families quicker. It is obviously better to obtain a longer sequence to separate sequences 
from different gene families into their respective different genes if applicable: this can be 
achieved using the current technology by sequencing the cDNA from both ends to 
produce a longer good quality composite sequence. 
1.5. The cDNA programme at the UK HGMP Resource Centre 
The cDNA sequencing program was initiated at the M R C funded U K Human Genome 
Mapping Project Resource Centre located at Northwick Park Hospital, Harrow, in the 
autumn of 1990. cDNAs selected at random from commercial oligi-dT primed, 
nominally full length, libraries were systematically sequenced using A . L . F . (Pharmacia) 
and the now obsolete Genesis (Dupont) machines, generating over 1050 usable ESTs as 
seen below: 
Library code Tissue/cell type No of usable sequences 
H Brain cerebral cortex (adult) 454 
B Liver (adult) 283 
T Rhabdomyosarcoma 88 
V Placenta 69 
Y Placenta 66 
O Bone marrow (adult) 61 
X Liver 28 
W Liver 20 
The bias of these libraries towards abundant mRNAs, and 3' end sequences, as reflected 
in the redundancy encountered during sequencing, necessitated the construction of 
libraries more likely to be representative of the mRNA populations from which they were 
derived. 
The "restriction fragment sorting" of complex cDNA populations was devised during 
1991 as a means of increasing the number of mRNAs accessible via a given cDNA 
library. The procedure is based upon the partitioning of cohesive-ended cDNA 
restriction fragments according to the sequence of their ends, by successive base-specific 
adaptoring and base-specific PCR. 
Fetal organ cDNA "libraries" totalling about 1600 clones (between 1-27 of a possible 
256 "subsets" represented in each library) were generated by restriction fragment sorting, 
from brain, adrenal, kidney, liver, and two different organ mixture mRNA sources. 
Analysis of some fragmentary sequences produced at this time, selected at random from 
a small number of different "subsets", strongly suggested that the technique yielded 
distinct subpopulations of cDNA fragments. 
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Library code Tissue/cell type No of usable sequences 
P Whole brain (fetal) 410 
S Adrenal (fetal) 302 
JG Kidney (fetal) 26 
A cDNA database, additionally containing sequences from other E C cDNA consortium 
laboratories, was established in 1992 using Sybase DBMS (originator Williams, G.). The 
facilities of the software included the detection and removal of spurious sequences like 
vector or adaptor; and the comparison of sequences with other nucleic acid sequences 
and protein sequences (in each possible reading frame) in the database, as well as those 
in E M B L and GenBank public databases. Further sophisticated software, namely 
I C A T O O L S (originator Parsons, J.), was also produced to classify sequences into 
families. 
About 4000 sequences had been produced by the E C cDNA consortium including the 
Resource Centre (Vickers, T.) , Genethon in Paris (Auffray, C ) , Genzentrum in Munich 
(Domdey, H. & Arnold, G.) and the Istuto di Biologia Cellulare in Rome (Tocchini-
Valentini, G.) by mid 1992. Some 1435 E S T s generated at the Resource Centre were 
submitted to the E M B L database at the end of the year. 
In order to make the fragmentary fetal organ cDNA clones accessible to a large number 
of laboratories, 15 024 E. coli clones (representing three fetal organ "libraries") were 
gridded at high density in 4x4 arrays on ten membrane filters using a Beckman Biomek 
automated workstation, facilitating hybridisation screening. Filter sets were dispatched 
to a total of 46 centres, and more than 750 individual clones have been issued to date. 
This study details further work mainly between 1992 and 1994 incorporating some of the 
established "in house" protocols: endeavouring to add modifications to improve the 
quality and efficiency where possible, the development of the available technologies, and 
new ideas and methodologies. A second generation of fragmentary fetal organ cDNA 
"libraries" was made and some of the clones sequenced. 
1. Intact and biologically active pure RNA free of chromosomal and mitochondrial DNA 
was fastidiously extracted from various fetal tissues using further optimised 
purification methods including ultracentrifugation. Standard methods and 
commercially available kits were used for mRNA purification and cDNA synthesis. 
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2. A variation of the pBluescript K S II (+/-) vector was produced to subsequently clone 
the prepared cDNA species which had been semi-ordered by restriction fragment 
sorting the cDNA population. 
3. Streptavidin bead capture of PCR products, and new methods involving the use of 
helper phage, filtration, and lacZ magnetic bead purification, were used to produce 
ssDNA templates for standard automated fluorescent Taq cycle sequencing using ABI 
373A DNA sequencers. 
Stringent screening of the sequencing data of the "second generation" fragmentary fetal 
organ cDNAs means that only ESTs of defined quality (<4% ambiguities between bases 
50-400) were processed for inclusion in the cDNA database and analysed further. 
Simultaneously in what is Ukely to be part of a significant move towards the functional 
analysis of ESTs , the Resource Centre more recently independentiy and through 
collaborative projects, investigated the feasibility of analysing transcription patterns via 
the non-radioactive in situ tissue and cellular localisation of cDNA probes. Indeed the 
cDNA fragments produced were compatible with producing such probes to investigate 
the biological significance, purpose and location of each sequenced cDNA which adds 
great value to them; putting the Resource Centre in a strong position compared to other 
institutions in development in this area. 
As a complement to the fragmentary cDNA libraries, 50 "full length" cDNA libraries 
were imported for further distribution of 100 ng ligation mixture ahquots for 
transformation. Functional cDNAs encoding cell-surface glycoproteins have been 
isolated from these libraries by expression screening, confirming the presence of full 
length cDNAs necessary for encoding properly folded and processed proteins. The 
identification of well characterised full length libraries, of established value, which would 
increase the repertoire of full length cDNA libraries available to the scientific community 
is in progress. 
Over 15 000 PCR amplified mixed fetal organ cDNA fragments (representing 19 subsets) 
were produced in order to generate more gridded filters. 
The Resource Centre relocated during 1994 to a new Genome campus also incorporating 
the Sanger Centre and European Bioinformatics Institute (EBI) , in Hinxton, just outside 
Cambridge. 
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1.6. Overview of methods utilised 
RNA extraction 
(CsTFA gradients) 
RNA to mRNA to cDNA 
(Oligo dT beads and cDNA synthesis kit) 
Production and HPLC 
purification of oligonucleotides 
(i.e. adaptors and primers) 
cDNA population restriction fragment sorting 
(i.e. cut with Fok I, size selections and purifications, ligation with adaptors 
gap filling, bead binding, NaOH wash, PGR titration, PGR and preparation for cloning) 
Vector construction 
Cloning of cDNA fragments 
(transformation) 
Picking and archiving of volumes 
Growth of clones 
PGR with one biotinylated primer 
and gel of sample to identify clones with insert 
< ^ 
Growth of ssDNA in PGR product bead binding 
Multiscreen plates (Streptavidin beads) 
and filtration 
Purification of ssDNA 
(lacZ beads) 
ssDNA sequencing templates 
Taq cycle sequencing 
(Fluorescentiy labelled sequencing reactions, computer generated chromatogram 
and automated base calling on ABI 373A and A.L.F. sequencers) 
Data transfer, editing and analysis 
(Sedit, IGATOOLS and BLAST database searches) 
Figure 1. The rapid identification of new transcribed human sequences. 
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1.6.1. R N A extraction 
Only genes that are being expressed are transcribed into messenger RNA (mRNA); so if 
this is used as starting material for a genomic Hbrary, the clones produced comprise only 
a selection of the number of genes in the cell, but all are actually being expressed in that 
cell type. Messenger RNA can not be ligated into a cloning vector, but it can be 
converted into DNA that can be, by complementary DNA (cDNA) synthesis utilising the 
properties of various enzymes. 
The isolation of pure good quality RNA from tissue is a prerequisite for cDNA synthesis. 
The main problem during the extraction procedure is protecting the RNA from 
degradation by ribonucleases, which are widely prevalent in the tissues and laboratory. 
The inclusion of the chaotropic salt guanidinium thiocyanate (GTC) in the primary 
extraction buffer provides a high degree of protection from RNase activity. RNA 
extracted in the G T C buffer can be purified further by equilibrium centrifugation in 
caesium chloride (CsCl), during which it becomes pelleted at the bottom of the 
centrifuge tube. In a recent improvement to this approach, CsCl was replaced with 
caesium trifluoroacetate (CsTFA) (Okayama et al, 1987), this is more effective in 
inhibiting RNase activity and deproteinising nucleic acids (Carter et ai, 1983). This 
improved procedure with further modifications has been utilised. 
The tissue of interest is homogenised in Extraction Buffer containing G T C . Cellular 
debris is removed by centrifugation. The extract is loaded in a bed of higher density 
C s T F A solution and centrifuged for over 36 hours. This leads to the formation of a 
density gradient, with protein floating on top (p < 1.25 g/ml), DNA banded within the 
gradient (p = 1.52 g/ml), and the RNA banded at a lower level within the gradient (p = 
1.62 g/ml). Following fractionation the RNA is loaded onto an identical gradient and 
centrifuged again for over 16 hours. RNA is recovered by standard ethanol 
precipitation. Selective precipitation of the RNA with 3M lithium chloride (LiCl) is then 
utilised for further purification. Standard phenol/chloroform and chloroform extractions 
are carried out before final ethanol precipitation of the total RNA. 
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1.6.2. mRNA purification and cDNA synthesis 
The use of the Dynabeads Oligo (dT)23 mRNA Purification Kit is based on the unique 
Dynabeads magnetic separation technology, and relies on base pairing between the poly 
(A)* residues at the 3' end of most messenger RNA and the oligo (dT) residues 
covalently coupled to the surface of the Dynabeads Oligo (dT)25. Other RNA species 
lacking a poly A segment (poly (A)" RNA), mainly rRNA and tRNA, do not form 
hydrogen bonds with the Dynabeads Oligo (dT)25 and are readily washed off. 
Purification of mRNA from total RNA 
cDNA synthesis 
Total RNA 
-T-T-T-T-T-T-T-T .Dynabeads Oligo (dTj.i 
-0- Binding 
-T-T-T-T-T-T-T-T poly (A)"" RiNA 
A-A-A-A-A-A-A-mRNA 
2x Wash 
•0^  Magnetic Separation Dynal MPC-E-1 
-T-T-T-T-T-T-T-T 
A-A-A-A-A-A-A-mRNA 
Eiution 
-O' Magnetic Separation Dynal MPC-E-1 
A-A-A-A-A-A-A-inRNA Pure mRNA 
First-Strand Reaction Mix 
5'I 
3'= 
5' 
3' 
0 
3 3" 
)• RNA: cDNA duplex 
Second-Strand Reaction Mix 
T4 DN.^ polymerase 
,and spin column 
3 3 
=5' Double-stranded cDNA 
Figure 2. The use of the mRNA purification kit and the basis for the cDNA synthesis 
procedure. 
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First-Strand cDNA synthesis is catalysed by Moloney Murine Leukemia Virus (MMLV) 
reverse transcriptase, using previously purified polyadenylated mRNA as template and 
oligo (dT)i2-i8 as primer: the conditions permit full-length transcription of RNAs. A 
modified procedure is used for second strand synthesis, in which RNase H nicks the 
RNA strand of the RNA: cDNA duplex formed, and DNA polymerase I uses the nicks to 
replace the RNA with DNA by nick translation. T4 DNA polymerase was used in 
preference to Klenow fragment to produce blunt ended cDNA following second strand 
synthesis. The cDNA produced is extracted with phenol/chloroform before further 
purification and size selection using SizeSep 400 Spun Columns (Pharmacia). The 
columns remove small molecules such as oligonucleotides, nucleotides, phenol and other 
by-products that could interfere with subsequent reactions, as well as rapid selection of 
cDNAs larger than about 400 base pairs. Purification is achieved using bench top 
centrifugation with minimal dilution in a suitable buffer, often avoiding precipitation. 
1.6.3. cDNA population restriction fragment sorting 
As mentioned previously the sequencing of cDNAs, as opposed to genomic sequencing, 
represents a rapid route to gene identification. But as many cDNAs in man occur in 
more than one of the 50 tissues, or 200 possible cell types, the probability of repeatedly 
identifying the same cDNAs is quite high. This problem is exacerbated by the fact that 
the cDNA libraries generally available are poorly representative of the tissues from which 
they are derived, being biased towards abundant mRNAs. 
Approaches for increasing the complexity of cDNA libraries (or normalisation) are 
necessary to minimise the redundancy encountered in systematic sequencing 
programmes. Restriction fragment sorting provides this means of subdividing complex 
cDNA mixtures into distinct semi-ordered subpopulations. In concept, individual subsets 
are of relatively low complexity, but combined provide access to a greater repertoire of 
genes than conventional cDNA libraries. 
The restriction fragment sorting of cDNAs is based upon the partitioning of cohesive-
ended cDNA restriction fragments according to the sequence of their ends. This 
necessitates the use of an enzyme which produces staggered cuts outside of its 
recognition sequence, so that any combination of bases is possible in the cohesive ends 
produced. The population of cDNA is digested with a type IIS restriction endonuclease. 
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generating fragments with non-identical cohesive ends. The number of different end 
sequences is 4", where n is the length of the overhang. 
A. nucleic acid or B. nuclt ic a c i d s 
I =3 ' 
Restriction endonuclease 
B a s e 
specific 
Q adaptoring 
Solid phase 
@ capture of 
adaplored 
material 
" B a s e specif ic 
priming 
Figure 3. Basic scheme for selecting specific restriction fragments. 
Fok I has an asymmetric pentanucleotide recognition sequence G G A T G (N) 9/13, 
(cutting DNA every 512 bp on average), and generates fragments with 4 base 5' 
overhangs. If the two ends of a Fok I fragment are considered independently, there are 
potentially 4* (65,536) fragment classes, each with a different pair of cohesive ends. 
Each base of a given Fok I cohesive end represents an identifier for the cDNA fragment 
possessing that overhang. If 4 bases divided between the two ends of a Fok I fragment 
are considered, 4'^ (256) different classes of fragment can be identified. 
Fok l site 
nnnnggalgnnnnnnnnnlnnnnnnnnnnnnnnnnnnnnnnnn 
nnnncctacnnnnnnnnnnnnninnnnnnnnnnnnnnnnnnnn 
Restriction endonuclease Fok 1 
Fokl 9 bases 
nnnnggatgnnnnnnnnn nnnnnnnnnnnnnnnnnnnnnnnn 
nnnncctacnnnnnnnnnnnnn nnnnnnnnnnnnnnnnnnnn 
13bases 
n - can be any base but is always [he same base at any 
point in a given sequence of DNA. 
I ^ sites of cleavage 
Figure 4. Nature of the cleavage produced by the restriction endonuclease Fok I. 
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cDNA fragments can be sorted into different subsets by successive base specific 
adaptoring, and base specific PCR. The selection of cDNA firagments by PCR serves to 
enrich the proportion of low abundance mRNAs, facilitating the subdivision of complex 
mRNA populations into subsets with a combined broad representation of cDNAs. 
The procedure by which 256 Fok I cDNA restriction fragment classes are recognised is 
first by base specific adaptoring. The specificity of the T4 DNA ligase reaction is 
employed to select for cDNA fragments with particular cohesive termini. Fok I cDNA 
fragments are ligated to two types of adaptor. A given specific adaptor, with specified 
bases at two positions within the 4 base 5' cohesive end, is capable of specific ligation to 
Vi6 of cDNA fi-agments which have complementary cohesive ends. 
Fokl 
5'11 gagga I g t ggtcagaa 
3' aac t CO t a c a c c a g t c 11 accg 
fragments produced by 
restriction cleavage 
tggccalatcccagiiga 3' 
gtatagggtcaaci 5' 
_5'tgnn 
adaptor 
Fokl 
5'11 gagga t g t ggtcagaai tgnn 
3' aac t cc I acaccag t c 11 accgt adaptor 
Anneal 
5 ' t tgagga tg tgg tcagaa tgnn 
3' aac t cc 1 acaccag I c 11 accg adaptor 
Ligase 
5' 11 gagga I g t ggtcagaa iggc 
3' aac t cc t acaccag t c 11 accg adaptor 
Only adaptors 
with 5' tgnn as 
5" tggc ligate 
successfully 
Figure 5. Base specific adaptoring at a Fok I cleavage site: specificity is introduced at 
two of the overhanging 5' bases of the adaptor. 
Solid-phase capture of cDNA fragments containing at least a single specific adaptor 
provides a means of selecting Vie of all Fok I cDNA fragments. Independent application 
of 16 different specific adaptors would enable a heterogeneous mixture of Fok I cDNA 
fragments to be fractionated into 16 "primary" subsets. 
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Base specific adaptoring and isolation of adaptored fragments 
Nucleic acids eg. c D N A s 
1.Restriction endonuc lcase 
1 \ eg. Fok I 
db ^ 
Non-specif ic 
adaptor mix eg 
Speci f ic 
biotinylated 
adaptor mix 
2. Ligation of adaptors 
IZB3 I ^ E Z Z ] 
I — ^ Es: 
153 
3. Bind to streptavidin coated 
magnetic beads and v/ash 
Figure 6. Selection for fragments produced by a type IIS restriction endonuclease: cuts 
are staggered and do not overlap the recognition site. 
The specificity of primer annealing and extension, as part of the PCR reaction, can then 
be utilised to further subdivide adaptored Fok I cDNA fragment "primary" subsets. 
Asymmetric PCR, employing a primer with a specified base at its 3'-terminus, will 
theoretically discriminate in favour of solid-phase captured single-stranded cDNAs 
containing a complementary base at position four of the 5' cohesive terminus of a non-
specific adaptor sequence. Four primers (3' "A", " C " , "G" and "T"), used 
independently, would partition each "primary" subset into 4 "secondary" subsets. 
A second selective round of amplification of specific solution phase single-stranded 
cDNAs can be achieved employing a primer 100% complementary to cDNAs with a 
given base at position four of the 5' cohesive end of a specific adaptor sequence. 
Amplification of each of the 64 "secondary" subsets with each of 4 specific primers (3' 
"A", " C " , " G " and "T") would generate 256 "tertiary" subsets. 
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Fokl 
5 ' t l gagga tg tgg l cagaa tgnn 
3' aac t cct acaccag t c 11 accg adaptor 
Fokl 
5' 11 gagga I g tgglcagaatggc 
3' aac t cc t acaccag t c 11 accg 
only adaptors where 5' nn 
were 5'gc ligated 
adaptor 
denature 
4 
5'ttgagga t g tggtcagaatggc[ 
adaptor 
3' gC 
primer 
3'g primer can only successlully 
prime 5' nc adaptored restriction 
Iragments 
5 ' t tgagga tg tgg tcagaa tggc | adaptor _ 
3'g 
5'11 gagga t g I gglcagaalggc 
3' aac t cc t acaccag t c 11 accg 
primer 
+ DNA polymerase 
adaptor 
primer 
Figure 7. Base specific priming of base specifically adaptored Fok I fragment. 
Base specific priming of DNA synthesis 
S3 i^S5=SS^§?^ 
1. Removal of the H 
un-bound strand 
eg. heat or alkali 
3' end of primer 
has specific 
mismatch 
2. Priming of DNA 3 'end of primer 
synthesis on a [ lias specific 
specific subset of U mismatch 
hound straiuls (cynics nf) 
3. Removal of the bound material and 
priming of DNA synthesis for a specific 
Bfcq ^ subset of complementary 
strands 
33 
Figure 8. Selection for fragments produced by a type IIS restriction endonuclease: cuts 
are staggered and do not overiap the recognition site. 
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1.6.4. Vector construction 
The oligonucleotide cassette was designed so it can be put into any vector containing 
unique Hind III and Sac I restriction sites within the multiple cloning site, and no Bbs I 
restriction site. Cutting with Bbs I (GAAGAC (N) 2/6) leaves non complementary 
overhangs for inmiediate directional cloning. 
Bbs I 
5' tcgccggtcttcggatccctgcaggaagactg 3' 
3' gccagaagcctagggacgtccttctgacggct 5' 
Bbs I 
The P C R primers were designed so that when the amplified cDNAs were treated with T4 
DNA polymerase and dTTP, the 4 base overhangs produced were complementary to 
those of the vector. Blue/white colour selection of the recombinants was retained in the 
appropriate vector. 
Alkali lysis involves adding three buffers to the pelleted DNA, which weaken the cell 
walls, before lysis and neutralisation. Relative volumes can be adjusted as required for 
the size of preparation required, but times, temperatures and mixing methods are critical 
to good yields of plasmids of the correct formation: yields of over 1 |jg per ml of culture 
should be obtained. Further removal of proteins and purification can be achieved by 
either phenol/chloroform methods, or using Qiagen tips which adsorb the DNA, washing 
off proteins and RNA from the salt column before eluting the plasmid DNA. Better 
quality DNA is obtained using columns, but is slower, more expensive, and not always 
necessary. 
1.6.5. Cloning of cDNA fragments 
The fetal liver cDNA library was constructed in the male (F') E. coli strain X L 1-Blue by 
standard cloning (Hanahan, 1983), of the adaptored Fok I generated cDNA fragments 
(majority 440-570 bp) into the pBluescript n KS (-1-/-), appropriately prepared. 
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1.6.6. Template production and sequencing 
Plasmid preparations could have been made by standard alkali lysis method, using Qiagen 
columns and protocols to manufacturers instructions, or any other commercially available 
products that produce good quality double stranded DNA for sequencing, but previous 
experience showed single stranded DNA (ssDNA) routinely reproducibly generates much 
better quality sequence data. 
Solid phase preparation of sequencing single stranded templates from polymerase chain 
reaction (PCR) products (Uhlen, 1989) is an accepted protocol for producing many good 
quality ssDNA templates. Excess primers impede good bead binding and priming of 
sequencing templates, and so were removed using S-400 HR MicroSpin Columns 
(Pharmacia). 
Single-stranded DNA represents the template of choice for dideoxy-chain termination 
DNA sequencing. The recombinant filamentous bacteriophage vector M13 is widely 
used to produce ssDNA for sequencing, since the DNA can be isolated with comparative 
ease and in high yields, for example using lacZ beads (Hawkins, 1992, and Watson et al, 
1993): but the unstability of the genomes of the bacteriophages in the presence of large 
inserts precludes the use of the conventional M13 vectors for the routine cloning and 
propagation of DNA. 
Phagemid vectors (plasmids containing a filamentous bacteriophage origin of replication) 
provide a means of generating ssDNA, while obviating the necessity for the subclonihg 
of fragments from plasmid to bacteriophage vectors. Superinfection of cells transformed 
with these plasmids using a suitable "helper" filamentous bacteriophage initiates 
packaging of single-stranded copies of these plasmids into progeny phage particles. 
The major disadvantage of phagemids is generally the low and irreproducible yields of 
ssDNA isolated following superinfection. This problem can be largely alleviated by 
selection of appropriate vector and helper phage. 
pBluescript II K S (+/-) (Short et al., 1988) is a double-stranded phagemid, which is 
treated as a plasmid with regard to the cloning of foreign DNA and the in vivo 
propagation of foreign DNA, following conventional transformation of E. coli. The 
"KS" signifies the orientation of a synthetic polylinker within the N-terminal coding 
22 
region of the P-galactosidase gene. The vector carries a specific fragment from the 
intergenic region of the f l filamentous phage, including the sequences required for the 
initiation and termination of viral DNA replication and for morphogenesis of 
bacteriophage particles. The (+/-) orientation of the f l origin of replication enables 
rescue of the (+) phagemid strand, following superinfection. 
Helper phage VCSM13 (Stratagene) is a derivative of M13K07 (Vierra & Messing, 
1987), a M13 (Messing, 1983) recombinant containing mutations in the bacteriophage 
origin of replication (insertion of lacZ sequences) and gene II (nucleotide transition). 
The single-stranded genome also possesses a plasmid origin of replication and a 
kanamycin resistance gene (to facilitate selection for infected cells). VCSM13 is 
resistant to interference with the replication of the helper phage DNA, effected by certain 
f l intergenic sequences present in some phagemids. The mutated VCSM13-encoded 
gene II product interacts less efficientiy with the M l 3 origin of replication than with the 
pBluescript f l origin of replication, and hence the majority of progeny single-stranded 
DNAs are derived from the phagemid. 
Since DNA purity and quantity are important prerequisites for "good" sequencing 
templates, diligent purification of the single stranded DNA is essential. The standard 
template preparation procedure involves the removal of bacterial cells from the phage 
culture by centrifugation, precipitation of phage, and simultaneous phage lysis and 
deproteinisation. The laborious nature of this procedure is not readily compatible with 
the automation or simultaneous processing of a large number of templates. 
Elimination of the need for centrifugation and precipitation permits the handling of 
samples in microtitre plate format and renders the ssDNA preparation adaptable to 
automation. The innovative growth of infected E. coli cultures in the 96-well filtration 
plate assemblies enables the efficient removal of bacterial cells by filtration, while 
selective purification is achieved by the specific hybridisation to the lacZ complementary 
paramagnetic bead-linked oligonucleotide. 
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Helper phage in Millipore Multiscreen 96-well filtration plates (3) 
Inoculation (96 at once), with cDNA clones 
Overnight growth at 37°C 
Application of vacuum and collection of filtrates 
Dynabeads lacZ Vector Purification Kit 
Lysation and hybridisation in 1.5 ml tubes in water baths 
Transference to a 96 format for washing of beads 
Eiution of ssDNA in 10 |j1 using Perkin-Elmer Cetus 9600 thermal cycler 
Checking of amount and purity on an agarose gel, (0.5 |il sample) 
Reconditioning and reuse of Dynabeads lacZ 
Sequencing of ssDNA template using 
PRISM Ready Reaction DyeDeoxy Terminator Cycle Sequencing 
Figure 9. The purification of ssDNA using lacZ beads. 
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The PRISM™ Ready Reaction DyeDeoxy™ Terminator Cycle Sequencing Kit (Applied 
Biosystems) is used specifically for preparing samples for sequence analysis on the ABI 
373A DNA Sequencer. Only the correct amounts of single or double stranded (ss or ds) 
template and primer (Ml3 (-20) G T A A A A C G A C G G C C A G T , an improved KS 
T C G A G G T C G A C G G T A T C , and T7 A A T A C G A C T C A C T A T A G were used), needs to 
be added to the DyeDeoxy terminator reagent to perform fluorescence based dideoxy 
sequencing in a single tube. The four dye-labelled dideoxy nucleotides: G, A, T and C 
DyeDeoxy terminators, replace the standard dideoxy nucleotides in enzymatic 
sequencing, incorporating a dye label into the DNA with the terminating base. This 
chemistry eliminates labelled false stops, and all four termination reactions can be 
performed in one tube. Thermal cycling of sequencing reactions increases signal 
intensity and decreases sensitivity to reaction conditions. Excess dye-labeUed dideoxy 
terminators have to be removed before the dye-labelled extension products are analysed. 
This is often done by the standard successive phenol/chloroform extractions although 
more efficient methods using various types of and spin-column chromatography 
including Biogel P6DG and S200, small and large columns are investigated. 
The Taq Dye Primer Cycle Sequencing Kit is also used specifically for preparing samples 
for sequence analysis on the A B I 373A DNA Sequencer. Four labelled primers (each 
labelled with a different A B I fluorescent dye) and standard dideoxynucleotides are used 
in standard enzymatic sequencing. 
Using standard overnight and quicker Basesprinter electrophoresis runs optimises the use 
of the available 373A sequencers for real time data collection. 
1.6.7. Sequence manipulation and analysis 
The A B I 373A sequence files, containing cDNA sequences in G C G format, are 
automatically categorised by "CDtotal", (originator Discala, C ) , as "Good" (<4% 
ambiguities between bases 50-400), "Intermediate" (4-6.6% ambiguities between bases 
50-400), or "Bad" (>6.6% ambiguities between bases 50-400). The artificial 
classification ascribed to each given sequence determines the nature of subsequent 
processing of that sequence. The "CDtotal" program additionally generates an 
experimental log displaying the continually updated progression in the accumulation of 
cDNA sequences (for each cDNA library, recording the number of cDNA sequences 
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falling into each of the three specified categories, the mean length of cDNA sequences, 
and the mean % of ambiguities between bases 50-400). 
Removal of cloning vector and adaptor sequences via a two stage screening procedure, 
involving the program "Sedit", (originator Williams, G.), is necessary prior to entry into 
the cDNA database and a standeu^ d "BLAST" search (Altschul et al., 1990), against the 
GenBank and EMBL databases respectively is completed. 
cDNAs from the fragmentary fetal organ cDNA libraries are sequenced in the "forward" 
and/or the "reverse" direction (using mainly the M13 Universal and KS primers, 
respectively). The manner in which the "Good" (<4% ambiguities between bases 50-
400) cDNA sequences are analysed is a reflection on the "Fok I cDNA fragment sorting" 
approach employed to construct the libraries. The restriction fragment sorting provides 
a means of subdividing complex cDNA mixtures into distinct subpopulations, and is 
based upon the partitioning of cohesive-ended cDNA restriction fragments according to 
the sequence of their ends. cDNA fragments are sorted into different subsets by 
successive base-specific adaptoring, and base-specific PGR. The analysis essentially 
involves evaluating the effectiveness of the restriction fragment sorting procedure at 
generating essentially distinct cDNA subpopulations. 
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2. MATERIALS AND METHODS 
2.1. RNA extraction 
2.1.1. Homogenisation and ultracentrifugation 
RNA was isolated and purified from various human fetal tissues, stored at -80°C, by 
homogenisation in Extraction Buffer containing guanidinium thiocyanate (GTC) 
(Pharmacia Biotech Limited RNA Extraction Kit), and equilibrium centrifugation in 
caesium trifluoroacetate (CsTFA) solution (Pharmacia Biotech Limited RNA Extraction 
Kit), (Okayama et al, 1987). 
A total tissue mass of between 0.5 and 1.0 grams for each of the six organ types was 
obtained, using samples for one organ type as necessary. 
Tissue Specimen Menstrual Mass (g) Total Extraction 
number age (weeks) mass (g) fluid (mis) 
Adrenal 11178 12.7 0.31 
11289 13.4 0.51 0.82 14.8 
Hand 11205 12.1 0.27 
11281 15.1 0.68 0.95 17.1 
Liver 11294 10.6 0.32 
11296 14.6 0.31 
11297 13.1 0.36 0.99 17.9 
Lung 11285 14.6 1.08 1.08 19.5 
Spleen 11285 14.6 0.25 
11347 14.0 0.10 
11384 15.1 0.15 
11391 15.1 0.18 
11393 15.4 0.13 0.81 14.6 
Stomach 11165 15.8 0.36 
11281 15.1 0.39 0.75 13.5 
Table 1. Mass and age of fetal tissues used. 
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Tissues were added to 18 ml of RNA Extraction Buffer per gram of tissue (Pharmacia 
Biotech Limited buffered aqueous solution containing guanidinium thiocyanate, N-lauryl 
sarcosine, and EDTA; density =1.15 g/ml). The tissues were in turn passed through an 
Ultra-turrax blade, (Ultra-turrax T 25), for about 30 seconds each, until a homogenate 
was formed. These were centrifuged at 2500 revolutions per minute for 20 minutes at 
15°C, in a Sorvall T6000B Centrifuge using a balanced swinging bucket rotor, to remove 
cell debris in preparation for ultracentrifugation. 
Modifications were made to the standard Pharmacia Biotech Limited RNA Extraction 
Kit procedure involving the use of CsTFA aqueous solution with a greater density of 2.0 
g/ml (Carter et al. 1983). The CsTFA was diluted to achieve an overall average density 
of approximately 1.55 g/ml with Extraction Buffer and tissue. CsTFA is hydroscopic and 
so was not left uncovered as a change in density would result. Using Beckman 
Polyallomer Quick Seal centrifuge tubes, 16x76 mm: 6.0 mis of CsTFA solution was 
used per tube (6x12=72 mis), as the total capacity of the each tube was 12.5 
mls:[(6.0x2)+(6.5xl.l5)=12.5xl.558]. 
Taking care not to disturb the pelleted material at the bottom of the tube: the required 
amount of the clarified homogenate in the extraction buffer, (6.5 mis), was removed and 
layered on to the CsTFA, filling each of the 12 tubes, 2 per tissue type. They were then 
sealed using a tube sealing device: in which the necks were melted with a metal cap on, 
moulded to seal the tubes; and left to cool to reset. 
The nucleic acids were centrifuged in CsTFA solutions at 120,000 gav (36K), for 42 
hours, at 15°C in a Beckman L7-65 Ultracentrifuge using a balanced Ti50 fixed angle 
rotor with metal caps on the tubes. 
2.1.2. Recovery of RNA 
The tubes were carefully removed from the ultracentrifuge, making sure not to dismrb 
the density gradients. Fractionation of the resultant bands were completed by collection 
of the contents of each tube from the bottom upwards through a 1.1 mm x 50 mm 
needle. The RNA band below the band of DNA was identified by a standard 
electrophoresed 0.85% (w/v) tris borate (IxTBE) agarose gel labelled with 0.5 ng/ml 
ethidium bromide, loading a 10 | i l sample from each vial and 1 | i l of DNA markers 
numbers 6 and 3, mixed with 2 | i l of 0.15% ficoU with bromophenol blue loading dye. A 
potential difference of 80 Volts was then applied across the gel running from negative 
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(black terminal), to positive (red terminal), for about an hour. The gel was then studied 
under a Ultra Violet light trans-illuminator with care wearing a protective face mask at 
all times: in which the ethidium bromide which intercalates with the RNA and DNA 
fluoresce. An image was taken, to examine the results of the electrophoresis further. 
From the location of luminescence on the gel, it was calculated which vials contain the 
required total RNA for each organ: these were then used further. 
The located RNA near the base of the tubes in the early fractions was then reloaded in an 
identical gradient in only 6 tubes, (the same tissue types were pooled), and re-centrifuged 
at 120,000 gav (36K), for 16 hours, at 15°C in a Beckman L7-65 ultracentrifuge using a 
Sw 41 Ti swing out rotor. 
Similar fractionation and electrophoresis procedures were again utilised to locate the 
bands of RNA. Standard ethanol precipitation purified and concentrated the RNA, 
whilst removing the CsTFA: 1/10 th volume of 2 M potassium acetate and 2.5 x volume 
of ethanol was added to the positively identified aliquots. Mixed samples were placed at 
-20°C to aid precipitation. 
Samples were centrifuged for 30 minutes in a Sorvall T6000B bench top centrifuge at 
2500 rpm. The supernatant was poured off, and the pellet resuspended in a total of 
about 1 ml 70% ethanol and transferred to a 1.5 ml tube. The RNA was then repelleted 
by microfuging at 13000 rpm for 30 minutes. The majority of the ethanol was poured off 
before pulse spinning and removing the remainder of supernatant by pipette. The RNA 
was briefly air dried, before dissolving in 360 | i l of TE buffer, (10 mM Tris-HCl, 1 mM 
EDTA, pH 7.5), on ice. 10 | i l could be examined by standard agarose gel 
electrophoresis on a 0.85% agarose gel. electrophoresis. 1050 ^1 (3 x volume) of 3 M 
lithium chloride was added to the remainder, and placed at 4°C overnight for selective 
precipitation of the RNA. 
Samples were microfuged at 13000 rpm for 30 minutes, and the supernatant was poured 
off. 500 | i l of 80% ethanol was added to each sample and mixed before another 10 
minutes microfuging. Again the supernatant was poured off, and after a brief spin excess 
fluid is pipetted o f f The pellet of RNA was then air dried before redissolving in the 
appropriate volume of water to allow for pooling of samples from the same tissues as 
necessary, to a total volume of 400 | i l . 
Standard phenol/chloroform and chloroform (Sigma), extractions were also carried out 
before final ethanol precipitation of the total RNA. 400 |LI1 of phenol/chloroform was 
added and mixed to each sample, and then microfuged at 13000 rpm for 5 minutes. The 
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supernatant was pipetted off and kept. The procedure was then repeated in full with 
chloroform. The RNA was again precipitated by ethanol precipitation in 1.5 ml tubes 
and placed at -20°C. 
The tubes were mixed and 40 ^1 samples taken, with the remainder of RNA stored at -
20°C. The samples were microfuged at 13000 rpm for 20 minutes, and the supernatant 
pipetted off. Fifty microlitres of 80% ethanol was added to each sample and mixed 
before another 10 minutes microfuging. Again the supernatant was pipetted off. The 
pellet of RNA was then air dried before redissolving in 40 | j l of water. 
20 | i l was then examined by electrophoresis on a 0.85% agarose gel, whilst the other half 
was used to take an optical density reading by adding water to a 0.4 ml total. Readings 
were taken at wavelengths of 260 and 280 nanometres to calculate the concentration, 
amount and purity of the RNA available for subsequent production of cDNA. 
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2.2. mRNA purification and complementary DNA (cDNA) synthesis 
The Dynabeads Oligo (dT)25 mRNA Purification Kit (Dynal), was used as instructed 
using 200 ^1 of beads for each 150 |ig of total RNA (a mix containing 25 |ig adrenal, 
hand, liver, lung, spleen and stomach RNA, and 150 |ig liver RNA). 
RNA was diluted to final volume of 200 | i l binding buffer (20 mM Tris-HCl, 1.0 M LiCl, 
2 mM EDTA, pH 7.5), and heated to 65°C for 2 minutes to disrupt secondary structures. 
This was added to 200 ^il of washed beads also in binding buffer, to hybridise for 5 
minutes at room temperature. The supernatant was removed after the tube had been in a 
Dynal MPC-E-1 magnet for over 30 seconds. The beads were washed twice out of the 
magnet with washing buffer (10 mM Tris-HCl, 0.15 M LiCl, 1 mM EDTA, pH 7.5), 
before removal of the supernatant as before The mRNA was eluted in 12.5 | i l elution 
buffer (2 mM EDTA), after heating to 65°C for 2 minutes, and immediately placing the 
tube in a magnet. After positive gel electrophoresis results of a sample from the first 
wash and elute the purified mRNA was used immediately. 
The standard cDNA Synthesis Kit (Pharmacia Biotech Limited), protocol was followed 
except T4 DNA polymerase was used instead of Klenow fragment for the production of 
blunt ended cDNA following second strand synthesis. 
First strand synthesis was completed by simply adding the 1-5 |ig of polyadenylated 
RNA in a total volume of 20 |J1 (diluted with RNase free water) that had previously been 
incubated at 65°C for 10 minutes and chilled on ice, to the First-Strand Reaction Mix 
(FPLCpure Cloned Murine Reverse Transcriptase, RNAguard, RNase- and DNase-Free 
BSA, oligo(dT)i2-i8 primer, dATP, dCTP, dGTP, and dTTP, in aqueous buffer) with 1 | i l 
of aqueous DTT solution added, and incubation at 37°C for 1 hour. 
The first-strand reaction (33 |al in total) was subsequently added to the Second-Strand 
Reaction Mix {E. coli RNase H and E. coli DNA polymerase I in aqueous buffer 
containing dNTPs) and the new volume of 100 | i l mixed by pipette action. This was 
incubated at precisely 12°C for 1 hour and 22°C for 1 hour, before inactivation of the 
enzymes at 70°C for 10 minutes and immediate chilling on ice. Eight units of T4 DNA 
polymerase (Boehringer Mannheim) were added and mixed before 30 minutes incubation 
at 37°C. At room temperature 100 |J1 of phenol/chloroform (Sigma) was added, the mix 
was vortexed before microfugation for 1 minute and collection of the upper aqueous 
layer. 
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After the phenol/chloroform extraction the double-stranded cDNA was purified and size 
selected using a standard SizeSep 400 Spun column (Pharmacia Biotech Limited), 
equilibrated in 50 mM NaCl, 10 mM Tris-HCl, pH 7.5. Each centrifugation was 
completed using a swinging bucket rotor in a Sorvall T6000B centrifuge at 1400 rpm for 
3 minutes precisely including acceleration and deceleration time. 
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2.3. cDNA population restriction fragment sorting 
Half of each of the cDNA products (60 ^1) were cut to completion with 8 | i l 4 U/fil Fok 
I enzyme (Boehringer Mannheim) in a total volume of 200 |al restriction buffer (10 mM 
Tris-HCl, 10 mM MgCh, 50 mM NaCl, 1 mM DTE, pH 7.5), at 37° for 2 hours, to 
generate cDNA fragments with unpredictable sequence at their termini. The activity of 
the restriction enzyme and reaction was tested on lambda DNA simultaneously and 
fragments observed by ethidium bromide agarose gel electrophoresis before proceeding. 
Purification was completed by two phenol/chloroform extractions and passing through 
SizeSep 400 Spun columns. 
Ohgonucleotides were synthesised on a 1 | i M scale using an Applied Biosystems 380B 
DNA Synthesiser, separated from ammonium hydroxide by rotary evaporation and 
purified by high performance liquid chromatography (HPLC) on a Beckman reverse 
phase column. They were quantified by U.V. absorbance spectroscopy using a 
conversion factor of 20 |ag/ml/A.U.26o. 
Half of the cDNA fragments were then mixed with 200 pmoles of each of the following 
adapters: 
Universal TT biotinylated adaptor 5' Bio GTTCTCGGAGCACTGTCCGAGA 3' 
Non specific 9 adapter 5' (N)4(N)4(N)4(N)4 TCCTTCTCCTGCACAGACA 3' 
Universal 9 adapter 5' TGTCTGTGCAGGAGAAGGA 3' 
and 200 pmoles of 1 from the possible 16 specific n adaptors: 
5' AA(N)4(N)4TCTCGGACAGTGCTCCGAGAAC 3' 
5' CA(N)4(N)4TCTCGGACAGTGCTCCGAGAAC 3' 
5' GA(N)4(N)4TCTCGGACAGTGCTCCGAGAAC 3' 
5' TA(N)4(N)4TCTCGGACAGTGCTCCGAGAAC 3' 
5' AC(N)4(N)4TCTCGGACAGTGCTCCGAGAAC 3' 
5' CC(N)4(N)4TCTCGGACAGTGCTCCGAGAAC 3' 
5' GC(N)4(N)4TCTCGGACAGTGCTCCGAGAAC 3' 
5' TC(N)4(N)4TCTCGGACAGTGCTCCGAGAAC 3' 
5' AG(N)4(N)4TCTCGGACAGTGCTCCGAGAAC 3' 
5' CG(N)4(N)4TCTCGGACAGTGCTCCGAGAAC 3' 
5' GG(N)4(N)4TCTCGGACAGTGCTCCGAGAAC 3' 
5' TG(N)4(N)4TCTCGGACAGTGCTCCGAGAAC 3' 
5' AT(N)4(N)4TCTCGGACAGTGCTCCGAGAAC 3' 
5' CT(N)4(N)4TCTCGGACAGTGCTCCGAGAAC 3' 
5' GT(N)4(N)4TCTCGGACAGTGCTCCGAGAAC 3' 
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5' TT(N)4(N)4TCTCGGACAGTGCTCCGAGAAC 3' 
These were denatured at 65°C for 3 minutes before incubation at 14°C for 16 hours with 
1 f i l (2.4 U/|il) T4 DNA hgase (Boehringer Mannheim) in a total volume of 90 |ils 
Ugation buffer (50 mM NaCl, 0.5 M Tris-HCl, 0.1 M MgClz, 0.1 M DTT, 1 mM 
spermidine, 10 mM ATP, pH 7.4). 
Excess adapters and reagents were removed by two phenol/chloroform extractions and 
passing through SizeSep 400 Spun columns. The adapted cDNA was heated to 78°C in 
a thermalcycler in a total volume of 200 |LI1 PCR buffer (50 mM KCl, 10 mM Tris-HCl, 
2.5 mM MgClz) and dNTPs (0.27 mM), and 2 ^ll (5 U/^1) Taq polymerase was added. 
The reaction was incubated first at 78°C for 5 minutes, and then 72°C for 10 minutes. 
80 | i l of Streptavidin beads (Dynal) were washed three times with 1 M NaCl, 100 mM 
Tris-HCl, pH 8.3, and resuspended in 200 50 mM NaCl, 100 mM Tris-HCl, pH 8.3. 
The beads were added to the cDNA reaction and incubated at 28 °C for 30 minutes 
(mixing every 5 minutes). The cDNAs on the beads were washed twice with 50 mM 
NaCl, 100 mM Tris-HCl, pH 8.3, four times with 0.15 M NaOH (with incubation for 5 
minutes at 28°C for each), twice in water and once in PCR buffer (2.5 mM Mg^^ 10 mM 
Tris, 50 mM KCl, pH 8.3); before resuspension in PCR buffer and dNTPs (0.2 mM 
dATP, dCTP, dGTP and dTTP). 
Two pmoles of 1 of the 4 possible specific 6 primers from: 
5' TGTCTGTCGCAGGAGAAGGAA 3' 
5' TGTCTGTCGCAGGAGAAGGAC 3' 
5' TGTCTGTCGCAGGAGAAGGAG 3' 
5' TGTCTGTCGC AGGAGAAGGAT 3' 
and 0.5 ]x\ (5U/|J1) Taq polymerase was added to the cDNA on beads in a total volume 
of 60 ^1. Under oil 16 cycles of PCR were completed: 95°C 30s, 65°C 2 min, 72°C 3 
min. 
30|J1 of Streptavidin beads were washed three times with 1 M NaCl, 100 mM Tris-HCl, 
pH 8.3, and resuspended in 30 ^ l 50 mM NaCl, 100 mM Tris-HCl, pH 8.3. 
The beads were added to the completed PCR and incubated at 28 °C for 30 minutes 
(mixing every 5 minutes). A magnet was applied to the beads, the supernatant removed, 
and used further after two phenol/chloroform extractions and passing through SizeSep 
400 Spun columns 
A fraction of the cDNA was set up in a PCR total volume of 40 |al including PCR buffer, 
dNTPs, and 2 pmoles of 1 of the 4 possible specific 0 primers from: 
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5' TGTCTGTCGCAGGAGAAGGAA 3' 
5' TGTCTGTCGCAGGAGAAGGAC 3' 
5' TGTCTGTCGCAGGAGAAGGAG 3' 
5' TGTCTGTCGCAGGAGAAGGAT 3' 
the same as before for that subset, and 2 pmoles of 1 of the 4 possible specific n primers 
from: 
5' GTTCTCGGAGCACTGTCCGAGAA 3' 
5' GTTCTCGGAGCACTGTCCGAGAC 3' 
5' GTTCTCGGAGCACTGTCCGAGAG 3' 
5' G T r C T C G G A G C A C T G T C C G A G A T 3 ' 
0.5 |al (5U/|il) Taq polymerase was also added. Under oil 5 cycles of PGR were then 
completed: 95°C 30s, 65°G 2 min, 72°C 3 min on a Techne thermal-cycler. 
20 pmoles of each of the relevant primers was added and a further 36 cycles were 
initiated. Every 4 cycles a sample of the PCR was taken and observed by standard 
agarose gel electrophoresis. The chosen PCRs (24, 28, or 32 cycles) were repeated 
under the same conditions with a further 10 minute 72°C extension cycle, again 
observing results before two phenol/chloroform extractions and passing the products 
through SizeSep 400 Spun columns. 
The cDNA products were incubated in a total volume of 100 | i l buffer (10 mM Tris-HCl, 
10 mM MgCl2, 50 mM NaCl, 1 mM DTE, 0.05 mM dTTP, pH 7.5), with 16 units T4 
DNA polymerase at 37° for 30 minutes. After two phenol/chloroform extractions the 
products were passed through SizeSep 300 Spun columns, ready for cloning. 
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2.4. Vector construction 
5 ^ig of pBluescript I I KS (+/-) phagemid was cut with 0.1 units Hind m and 0.3 units 
Sac I in a volume of 100 | i l 33 mM Tris acetate, 10 mM Mg-acetate, 66 mM K-acetate, 
0.5 mM DTT, pH 7.9 for 2 hours at 37°C, after a suitable titration to optimise 
conditions. After two phenol/chloroform extractions and passing through SizeSep 400 
Spun columns; 1 |ag of product was added to 100 pmoles of both: 
5' AGGTTTGGGCGGTCTTCGGATCCGTGGAGGAAGACTGGCGAGAGCT 3' 
5' CTGGCCAGTCTTCCTGCAGGGATGCGAAGACCGCCGAA 3' 
or 
5' AGGTTTCGCCGGTCTTCGGATCCCTGGAGGAAGACTGCCGAGAGCT 3' 
5' GTCGGCAGTGTTCGTGCAGGGATCCGAAGACCGGCGAA 3' 
This was denatured at 65°C for 3 minutes before adding 0.24 units T4 DNA Ugase to a 
total volume of 40 |al ligation buffer (50 mM NaCl, 0.5 M Tris-HCl, 0.1 M MgClz, 0.1 
M DTT, 1 mM spermidine, 10 mM ATP, pH 7.4), and incubation at 16°C for 16 hours. 
After purification 1 unit of T4 polynucleotide kinase was added to a total volume of 100 
Ml buffer (50 mM NaCl, 0.5 M Tris-HCl, 0.1 M MgCh, 0.1 M DTT, 1 mM spermidine, 
10 mM ATP, pH 7.4) and incubated at 37°C for 30 minutes. 
Standard transformation protocols (Hanahan, 1983), were then utiUsed to grow plasmid 
colonies containing the cassette into E. coli on colour selective LB agar plates. E. coli 
(strain XLl-Blue) was incubated at 37°C in 100 ml LB broth to log phase (O.D.55o= 0.5 
A.U.; approx.lO* cells/ml) in preparation. The cells pelleted by centrifugation and the 
supematent poured o f f They were then resuspended in 50 ml 50 mM CaGl2 
transformation buffer, and left on melting ice for 2 hours or more. 
Ten microlitres of each ligation mixture was diluted with 100 | i l of T.G.M. (10 mM Tris-
HGl, 10 mM CaCla and 10 mM MgClz), and cooled on ice in 15 ml polypropylene tubes 
(Falcon). Competent E. coli cells were again pelleted by centrifugation and the 
supernatant poured o f f They were then resuspended in 5 ml 50 mM CaCla. 200 | i l of 
competent cells were added with stirring, the tubes rolled, and incubated on ice for 30 
minutes. Following heat shock at 42°C for precisely 1 minute, 1 ml of LB broth was 
added, and the transformed cells incubated with shaking at 37°C for 1 hour. The cells 
were then spun down, the supernatant poured of f and the pellet resuspended in the 
residual liquid. This was spread onto pre-warmed LB agar plates containing 50 |ig/ml 
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ampicillin, 12.5 |ig/ml tetracycline, 0.02 g/ml X-gal in DMF, and 0.024 g/ml IPTG. The 
plates were incubated for 15 hours at 37°C and then transferred to 4°C for 1-2 hours. 
Cells transformed by Bluescript plasmid (Tet" )^ containing inserts interrupting the lacZ 
gene would be expected to grow as white colonies unless the reading frame was 
preserved. 
In this case blue colonies were picked from the transformation plates into 2 ml of LB 
broth with ampicillin in bijous. These were incubated with shaking at 37°C overnight, 
from which plasmid preparations were made by alkali lysis methods (Sambrook et al., 
1989). The cultures were microcentrifuged to form a bacterial pellet, which were 
resuspended in 100 | i l ice cold solution 1 (50 mM glucose, 25 mM Tris-HCl, 10 mM 
EDTA, pH 8.0). Twice the volume fresh ice cold solution 2 (0.2 M NaOH, 1% SDS), 
were added, and the tubes inverted several times. To each sample 150 |J1 of ice cold 
solution 3 (3 M potassium acetate) was added before brief mixing, and incubation on ice 
for 3-5 minutes. After microfugation at 13000 rpm for 5 minutes at 4°C the supematants 
were removed for further phenol/chloroform and chloroform extraction purifications. 
The pure DNA samples were then precipitated by standard ethanol precipitation. 
After the plasmid containing the cassette had been positively identified by restriction 
analysis, large scale plasmid preparations were made using standard Qiagen methods. 
These involved a protocol similar to alkali lysis: equal suitable volumes of the supplied 
solutions PI , P2 and P3 were used and added in the same manner. After centrifugation 
the supematants were loaded on to a Qiagen tip, and adsorbed, suitable volumes of QB 
were applied and eluted before three separate additions and elutions to each tip of the 
same volume of QC. The required elutions produced after the applications of QF were 
collected in fresh tubes. Isopropanol (0.7 x volume) was added to precipitate the DNA, 
which was washed with 70% ethanol after centrifugation before redissolving in TE. 
About 32 |ig of product was cut with 8 | i l Bbs I (4 U/|il) in a total volume of 160 |J1 10 
mM Bis Tris Propane-HCl, 10 mM MgCla, 1 mM DTT, pH 7.0 at 37°C for 2 hours; to 
produce 4 base overhangs in the plasmid ready for insertion of cDNAs prepared for 
cloning. A subsequent incubation with hgase at 16°C for 16 hours was set up to show 
no ligation occurs between the non complementary endings: 5' GCGA 3' and 5' CCGA 
3', or 5' CCGA 3' and 5'GCGA 3'; other controls were also set up. 
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2.5. Cloning of cDNA fragments 
Ten microlitres of the prepared cDNAs were ligated into 2 | i l of vector using 2 units of 
T4 DNA ligase in a total volume of 20 ^1 buffer (50 mM NaCl, 0.5 M Tris-HGl, 0.1 M 
MgCl2, 0.1 M DTT, 1 mM spermidine, 10 mM ATP, pH 7.4), and incubating at 14°C for 
16 hours. The vector containing insert were cloned into E. coli strain XLl-Blue host 
cells using standard competence and transformation protocols (Hanahan, 1983). These 
were slightly more refined than those used previously involving Hanahan transformation 
buffer instead of CaCl2 solution. 87.5 |al of DMSO was added to competent cells 
resuspended in 2.5 mis buffer and kept on ice for 5 minutes, before addition of the same 
volume of DTT, and incubation on ice for 10 minutes. Finally 87.5 | i l DMSO was 
added, mixed gentiy and kept on ice for a further 5 minutes, before adding 200 | i l 
aliquots of cells to the various ligation mixes including controls. After incubation on ice 
for half an hour, exactly 90 seconds at precisely 42°G, and placing on ice for 2-3 
minutes, 800 ^1 of SOC broth was added. Colonies and controls were plated out in the 
residual after incubation at 37°G with shaking, before centrifugation and removal of 
supernatant. They were grown at 37°C for 16 hours on LB agar plates containing 
antibiotics (ampicillin and tetracycline) and blue/white colour selection (X-gal and IPTG) 
as before. White colonies were picked into wells containing 100 ^1 of LB broth and 50 
|ag/ml ampicillin per well. The colonies were duplicated into another microtitre plate and 
also stamped onto a LB agar plate, before incubation for 16 hours at 37°C. Standard 
glycerol stocks were made and stored frozen (Sambrook et al., 1982). The clones on the 
agar plates were ready for subsequent PGR, helper phage inoculation or standard plasmid 
preparations to produce suitable template for sequencing. 
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2.6. Template production and sequencing 
2.6.1. Template preparation from PCR products 
The protocol used was as documented in detail by Sibson, D.R., in Chapter Twenty-One: 
Solid Phase Preparation of Sequencing Templates from PCR Products, of Automated 
DNA Sequencing and Analysis (Adams, Fields & Venter (eds), 1994), with working 
improvements added in accordance with the author. 
Standard PCRs were set up from the clones grown on selective media using 20 pmoles 
of forward (5' GTAAAACGACGGCCAGT 3') and reverse (5' AACAGCTATGACCA 
TG 3') primers, one of which was 5' biotinylated, in a total volume of 40 | i l PCR buffer 
and dNTPs, and 1 unit of Taq polymerase. These were kept at 95°C for 1 minute and 
then cycled 35 times: 95°C 30s, 60°C 30s, 72°C 40s, before a 5 minutes extension cycle. 
Excess primers were removed by passing the products made up to 60 | i l with water 
through Pharmacia S-400 HR MicroSpin Columns as instructed using Beckman inserts 
to hold 1.5 ml tubes for use in the Sorvall benchtop centrifuge for ease and efficiency of 
throughput (24x4=96 at once). 
M-280 Streptavidin beads (Dynal) were prepared for use by washing them in 1 M NaCl, 
10 mM Tris-HCl, pH 8.3, (30 [i\ of beads per reaction), and resuspending them in 50 
mM NaCl, 10 mM Tris-HCl, pH 8.3. The biotinylated products were then bound to the 
streptavidin coated beads by incubating at 28 °C for 30 minutes in a Techne 96 well plate 
on a Techne hotplate with regular mixing. After washing the beads-double stranded 
DNA twice with 50 mM NaCl, 10 mM Tris-HCl, pH 8.3 using a Dynal MPC-96 magnet 
the non biotin containing strand was removed by incubation twice at 28°C for 5 minutes 
in fresh 0.15 M NaOH. The bead bound products were finally washed twice with water 
before resuspension in a suitable volume of water (10 |al) ready for sequencing. 
2.6.2. DNA purification using lacZ beads 
Each well of a 96-well plate (Falcon 3072 Microtest HI tissue culture plate), containing 
100 |J1 of LB (supplemented with 50 |ig/ml ampicillin and 12.5 |ig/ml tetracycline) per 
well, was inoculated with an E. coli fetal liver cDNA clone from a 25% glycerol stock 
microtitre plate maintained at -20°C. The ninety six clones were grown overnight at 
37°C with shaking. 
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The clones were stamped onto LB + 1.5% bacto-agar (supplemented with 50 ng/ml 
ampicillin and 12.5 |ag/ml tetracycline) in a single well plate (Dynatech Laboratories Inc. 
MIG-2000 Inoculum tray) and cultured for a further 16 hours at 37°C. 
The E. coli clones were stamped into three 96-well filtration plate assemblies (Millipore 
Multiscreen 0.45 |jm, triton-free, mixed cellulose acetate/cellulose nitrate ester filter), 
standing on microtitre plate lids (Dynatech Laboratories Inc): each well contained 250 | i l 
of VGSM13 (~1 xlO^ pfii/ml) in 2 x YT broth (1.0% bacto-yeast extract, 1.6% bacto-
tryptone, 0.5% NaCl, pH 7.0), supplemented with 50 |ig/ml ampicillin. The cultures 
were grown with agitation (170 rpm) for 2 hours at 37°C. Kanamycin was added to 
each culture (final concentration 50 ^g/ml), and the 3 x 96 clones were grown for a 
further 22 hours at 37°G. 
The 96-well filtration plates were placed, in turn, onto a vacuum manifold and a vacuum 
applied to effect removal of bacterial cells from the phage supematants by filtration. The 
filtrates from the three plates (3x~200 ^ 1) were collected in to a single 96 deep-well titre 
plate (Beckman), (i.e. each of the ninety six phage supematants was the product of three 
250 |J1 VGSM13-infected E. coli cultures). Aliquots (10 |il) of a representative number 
of phage filtrates were analysed by agarose gel electrophoresis, to confirm that adequate 
yields of single-stranded phagemid DNA had been obtained before proceeding to purify 
the phagemid DNA further. The use of filtrate as opposed to the phage supernatant 
separated from the bacteria by centrifugation, with regard to both quality and throughput 
was evaluated. Single-stranded phagemid DNA (+ strand) was purified from the cleared 
phage filtrates by hybridisation to Dynabeads lacZ vector purification kit protocol (Fry et 
al., 1992), unless otherwise indicated*. Dynal lacZ beads are streptavidin-coated 
paramagnetic beads, linked to which are biotinylated 40-mers complementary to a (+) 
strand sequence within the 5' regulatory region of the lacZ gene, present in M l 3 and 
M13-derived cloning vectors. The ninety six 600 | i l phage filtrates were transferred from 
the deep well microtitre plate into individual 1.5 ml microcentrifuge tubes. The phage 
particles were lysed by the addition of 100 ^il of 1.5% SDS, 0.125 M EDTA, and 
incubation (with mixing) at 75°C for 15 minutes. To each lysate, 200 |xl of 20% PEG 
was added and 0.9 mg* (90 |il) of Dynabeads lacZ (determined by suitable titration to be 
sufficient), resuspended in 180 fil* of 6.5M sodium perchlorate. The phagemid DNA 
was hybridised with the lacZ beads by incubation at 45°C' for 30 minutes, mixing 
periodically to resuspend the beads. The majority of the supernatant (-1000 |ul) was 
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removed from each tube using a Dynal MPC-M Magnetic Particle Concentrator (holds 
up to ten separate 1.5ml microcentrifuge tubes), to concentrate the paramagnetic beads, 
and the lacZ beads in each tube were resuspended in the residual -80 | i l volume and 
transferred to individual microAmp tubes (Perkin-Elmer) held in a GeneAmp 9600 
microtube rack (Perkin-Elmer). The remaining 80 ^1 of supernatant was removed from 
each tube, and the lacZ beads were washed twice in 300 |xl of 10 mM Tris-HCl (pH 8.0), 
1.0 mM EDTA. The purified single-stranded phagemid DNA was eluted from the lacZ 
beads by the addition of 10 |al of 10 mM Tris-HCl (pH 8.0) to each sample, and 
incubation (Perkin-Elmer 9600 thermal cycler) at 70°C for 5 minutes and removal of 
elute whilst using a Dynal MPC-9600 Magnetic Particle Concentrator (holds Perkin-
Elmer GeneAmp 9600 microtube rack). An aliquot (0.5 |ul) of each of the ninety six 
elutes was examined by agarose gel electrophoresis to assess the purity and quantity of 
single-stranded phagemid DNA prior to sequencing. Beads were reconditioned using 0.1 
M NaOH before reuse at least once. 
Customised home made beads (Hawkins, 1992) were also made and evaluated briefly. 
The biotinylated oligonucleotide complementary to a part of the lacZ-region in different 
vectors was hnked to Streptavidin beads through the biotin-streptavidin system. The 
DNA probe was an oligonucleotide 40-mer (5' TT ATC CGC TCA CAA TTC CAC 
ACA ACA TAC GAG CCG GAA GC 3'), complementary to the (-I-) strand of 
pBluescript I I KS (+/-). One milMgram per 100 |al of stock streptavidin beads were 
transferred to a 1.5ml Eppendorf tube, and put on a MPC-E magnet, to remove the 
supernatant, before washing with 200 |J1 of TTL buffer (100 mM Tris-HCl, pH 8.0, and 
0.1% Tween 20, 1 M LiCl), and resuspension in 20 | i l of TTL buffer. 25 pmoles of the 
HPLC purified biotin oligonucleotide was coupled to 1 mg (100 |il) of streptavidin, and 
incubated for 15 minutes at room temperature in the TTL buffer. The lacZ beads were 
then placed in a magnet to remove the supernatant, before washing with 0.15 M NaOH 
to remove any non-specifically bound probe. They were washed twice in TT buffer (250 
mM Tris-HCl, pH 8.0, and 0.1% Tween 20) before incubation at 80°C for 10 minutes in 
TT buffer. They were then placed in a magnet and the supernatant removed again to 
remove any unstable biotin streptavidin couplings. Finally the lacZ beads complex were 
taken up in 100 | i l hybridisation mixture, (6.5 M NaClO )^ or 100 | i l storage buffer, (250 
mM Tris-HCl, pH 8.0, 20 mM EDTA, 0.1 % Tween-20, 0.02% Sodium azide) to be 
ready for use. 
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2.6.3. Automated fluorescent sequencing 
Sequencing of the ssDNA template was performed using standard ABI 373A sequencers 
with some Taq Dye Primer Cycle Sequencing but mostly PRISM Ready Reaction Dye 
Deoxy Terminator Sequencing Kit chemistry. 
Slight alterations were made to improve the thermocycUng protocols (30 cycles: 96°C, 
20s; 50°C, 10s; 60°C, 4 minutes), (Rosenthal, 1992). Excess terminator removal 
methods utihsed varied: one method used phenol/chloroform extraction and spin 
columns. First the columns were prepared for use: fresh Biorad Biogel P6DG gel (10 
g/lOOml in 50 mM NaCl, 10 mM Tris-HCl, pH 7.5-HCl) or Pharmacia Sephacryl-200 
(MicroSpin S-200 HR by Pharmacia were also used), was loaded in to new large empty 
spin columns to a slurry depth of 3 cm or small columns to a depth of 2 cm. After 
elution, 3 ml of H^O was loaded to each column and eluted (or centrifuged through). 
Columns were centrifuged at 1400 rpm for 3 minutes. For ease of use the smaller 
columns were preferred as these could be centrifuged (not microfuged as instructed) in 
6x4 arrays (Beckman) allowing 96 samples to be processed at once. 20 |ul of water was 
added to the thermal cycled extension products to be purified which were removed from 
storage at 4°C or -20°C (as necessary). 40 |LI1 of phenohH^O: chloroform (68:18:14), 
was added to each tube, before replacing lids on tightiy and vortexing for 60 seconds. 
They were centrifuged in the Sorvall centrifuge at 3000 rpm for 5 minutes carefully 
balanced. The 40 |al supematants from the samples were loaded on to the columns 
before centrifugation at 1400 rpm for 3 minutes. Samples were placed in the Aquavac to 
dry down. The pellets were carefully resuspended in 3.5 microlitres formamide/50 mM 
EDTA (5:1 v/v) by vortexing and microfuging. Prior to loading the samples are heated 
on a heating block at 90°C for 2 minutes, and then immediately placed on ice. They 
were stored for at 4°C at this stage as necessary. Columns were reusable after gel matrix 
was cleaned with 3 volumes 0.2% NaAzide, and washed through with water. Other 
protocols were evaluated throughout for yield and quality of cleaned products. 
Standard 24 cm well to read, and 0.4mm thick sequencing plates were used throughout. 
The 373A DNA Sequencer (Applied Biosystems) was set up as instructed by the 
manufacturers. Other settings and parameters were chosen and altered as required: 
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Parameter Full Scan BaseSprinter 
Time (hours) 12 6 
Power (watts) 30 40 
WeUs 24 or 36 18 
PMT voltage 780-820 880-920 
Gel concentration 6% 4.75% 
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2.7. Sequence manipulation and analysis 
After necessary retracking and reanalysis (see ABI373A Users Manual), the raw data 
was transferred from the sequencer assigned Apple Macintosh to an edit Apple 
Macintosh where a hard copy was made on to optical disk using a Panasonic WORM 
system. The data was then transferred in gcg format with trace files using an ethemet 
connection to a Unix directory accessed by a DECpc system. 
The ABI 373A sequence files, containing cDNA sequences in GCG format, were used as 
the input files for a program, "CDtotal", (originator Discala, C ) , which categorised 
cDNA sequences as "Good" (<4% ambiguities between bases 50-400), "Intermediate" 
(4-6.6% ambiguities between bases 50-400), or "Bad" (> 6.6% ambiguities between 
bases 50-400). The artificial classification ascribed to each given sequence determined 
the nature of subsequent processing of that sequence. The "CDtotal" program 
additionally generated an experimental log displaying the continually updated progression 
in the accumulation of cDNA sequences (for each cDNA library, recording the number 
of cDNA sequences falling into each of the three specified categories, the mean length of 
cDNA sequences, and the mean % of ambiguities between bases 50-400). 
cDNA sequences of "Intermediate" quality were edited (where possible), so that upon 
re-characterisation (re-evaluation using "CDtotal") they could be ascribed the "Good" 
classification. Editing featured the use of the Staden program, "Trace EDitor", to view a 
given trace file for possible characteristic DNA sequencer-specific base-calling errors, 
combined with the application of the GCG program, "Seqed", to appropriately edit the 
corresponding sequence file. 
cDNA sequences classified as "Good" (0-3.7% ambiguities between bases 50-400), were 
validated prior to entry into the cDNA database through the removal of cloning vector 
and adaptor sequences via a two stage screening procedure, involving the program 
"Sedit", (originator WiUiams, G.), and a "BLAST" (Altschul et al, 1990). search against 
the GenBank and EMBL databases, respectively. 
The analysis essentially involved evaluating the effectiveness of the restriction fragment 
sorting procedure at generating essentially distinct cDNA subpopulations. 
cDNA sequences (prior to the removal of adaptor sequences) were screened for the 
expected subset-specific adaptor and PCR primer pair selecting bases, and for the 
presence of Fok I sites (both at the 5'-end and internal), using the GCG program 
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"findpattems". The program "CDpattem" displayed the output of "findpattems" in 
tabular format. 
The reverse compliments (= forward sequences) of cDNAs sequences (following the 
removal of vector and adaptor sequences) generated using the KS sequencing primer 
(reverse direction sequences) were obtained employing the GCG program, "REVERSE". 
The GCG programs, "FASTA" and "GELMERGE", were utilised to identify overlaps 
between the forward sequence and the reverse compUment of the reverse sequence of 
cDNAs for which both strands were sequenced. Where significant overlaps were 
identified, the forward sequence and the reverse compliment of the reverse sequence of a 
given cDNA were merged to construct a composite sequence, either utilising the 
consensus file output of "GELMERGE", or by manual editing. Where genuine overlaps 
could not be detected, the longer of the two sequences (forward sequence, or the reverse 
compliment of the reverse sequence) was selected for analysis. 
The cDNA fragment composition of each subset was assessed by analysis of sequences 
(composite, or forward/reverse compliment of the reverse) using a program that indexes 
sequences sharing similarities into classes (^'ICAass", originator Parsons, J., groups 
sequences which are approximately repeated within the length of another). Each class 
(family of sequences, or unique sequence) was characterised by similarity search 
("BLAST") of its members against the GenBank database. 
The cDNA fragment composition of each subset was then assessed by clustering the 
sequences into classes (family of sequences, or unique sequence) according to the highest 
scoring (best alignment) GenBank database sunilarity of each sequence ("CDcheck" 
program). 
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3. RESULTS 
3.1. Quality of RNA and cDNA libraries 
The first ultracentrifugation fractionated the RNA from the chromosomal and 
mitochondrial DNA successfully (Plates 1 & 2 ) , with the second ultracentrifugation 
removing further DNA still present. 
V I 1 2 3 4 5 6 7 S 9 10 11 1213 14 1516 17 l i l 9 
nnm 
Plate 1. Ultracentrifugation density gradient fractionation of liver fetal tissue. 
0.85 % T B E agarose gel stained with ethidium bromide: gel affected by C s T F A salt in samples. 
20 \i\ samples: 1-19 fractionations from the base up: 3-8 RNA, 11-19 D N A and proteins. 
1 |al D N A molecular weight marker V I . 
V I 1 2 3 4 5 6 7 8 9 10 11 1213 14 1516 17 IS 19 
Plate 2 . Ultracentrifugation density gradient fractionation of lung fetal tissue. 
0.85 % T B E agarose gel stained with ethidium bromide: gel affected by C s T F A salt in samples. 
20 \i\ samples: I - I 9 fractionations from the base up: 6 RNA, 15-19 D N A and proteins. 
1 |al D N A molecular weight marker V I . 
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The high quality of the purified total RNA was observed (Plate 3), and values between 
1.8 and 2.0 for (OD26o/OD2go) indicated pure samples. Yields were variable between 
47.0 jug and 682.1 jiig (Table 2) depending on the nature of the fetal tissue. 
Tissue OD260 OD280 Purity Concentration Total 
(OD260/OD280) (Mg/ml) (Mg) 
Adrenal 0.074 0.034 2.18 59.2 82.9 
Hand 0.042 0.022 1.91 33.6 47.0 
Liver 0.609 0.315 1.93 487.2 682.1 
Lung 0.328 0.162 2.02 262.4 367.4 
Spleen 0.075 0.040 1.88 60.0 84.0 
Stomach 0.125 0.066 1.89 100.0 140.0 
Table 2. Purity and yield of RNA extracted. 
1 2 3 4 5 6 V I m 
I i 
**** VMI 
-2176 
'1033 
Plate 3. Total RNA. 
5 | i l samples: 1 Adrenal, 2 Hand, 3 Liver, 4 Lung, 5 Spleen, 6 Stomach. 
1 pi D N A molecular weight marker V I (Boehringer Mannheim), pBR322 D N A B g / I + pBR322 
D N A / / / / i / I , solution in 10 m M Tris -HCl , 1 m M E D T A , pH 8.0, 0.25 pg/pl. 
Fragment sizes: 2176, 1766, 1230, 1033, 653, 517,453, 394, 298, 234, 220, 154 base pairs. 
1 pi D N A molecular weight marker HI (Boehringer Mannheim), X DNA EcoR I + Hind HI, solution in 
10 m M Tr i s -HCl , 1 mM E D T A , pH 8.0, 0.25 pg/^l. 
Fragment sizes: 21226, 5148, 4973,4268, 3530, 2027, 1904, 1584, 1375, 947, 831, 564, 125 base pairs. 
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The mRNA purification was shown to be successful by observing a sample of the first 
supernatant from the beads and a sample from the elute. The supernatant contains 95-
97% of the total RNA, and the elute only about 3-5%. 
raVI 1 2 3 4 n i V I 12 3 4 
Plate 4. mRNA purification: two different exposures. 
20 1^ supernatant containing total RNA: 1 Mix: adrenal, hand, liver, lung, spleen and stomach, 2 Liver. 
2.5 pi elute containing mRNA: 1 Mix: adrenal, hand, liver, lung, spleen and stomach, 2 Liver. 
2 |al D N A molecular weight markers V I and HI. 
Much experimentation and quality control of products was required throughout the 
construction and production of the new vector ready for insertion of the prepared 
cDNAs. Firstly a titration of Hind I I I and Sac I restriction enzymes to be used had to be 
performed to optimise the cutting of the original pBluescript 11 KS (+/-) vector to 
produce a site suitable for insertion of the oligonucleotide cassette: and an actual check 
of the double digestion before ligation with adaptors 
V I 1 2 3 4 5 6 7 8 9 1011 1213 1415 16 V I 1 2 
Plate 5. Restriction endonuclease titration. Plate 6. pBluescript I I KS (+/-) 
2 |il D N A molecular weight marker V I . cut with Hind I I I and Sac I . 
15 pi samples: 1 & 9 no enzyme; 2-8 Hind III after 0, 1, 2, 2 pi D N A marker V I . 
4, 8, 16, & 32 minutes; 10-16 Sac I after 0, 2, 5, 10, 20, 30 1 j 1^ yn -^ut Bluescript K S ; 2 20 pi 
& 60 minutes. sample K S cut with Hind I II and Sac I . 
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After transformation a small plasmid preparation and restrictions confirmed some of the 
picked clones contained the correct insert in the cloning site. Large scale Qiagen plasmid 
preparations then produced a greater yield of pure plasmids containing the insert. From 
fluorimeter readings taken concentrations of each preparation were calculated. 
1 2 3 4 5 6 7 8 9 1011 1213 1415 l 6 V i m i 7 l 8 1 2 3 4 V i m 5 
Plate 7. Positive identification of vector 
containing insert. 
2 pi D N A molecular weight markers V I & III . 
1-4 clone 1,5-8 clone 2, 9-12 clone 3 & 13-16 clone 4. 
1, 5, 9 & 13: no enzyme, not cut. 
2, 6, 10 & 14: EcoR I cut, cuts original K S only. 
3 ,7 , 11 & 15: P j f I cut, cuts original and vector with insert. 
4, 8, 9 & 16: Bbs I cut, cuts only vector with insert. 
17 uncut circular K S , 18 cut hnear K S . 
Plate 8. Plasmid preparations of 
vector containing insert. 
2 lal D N A markers V I & IH. 
1-4 1 pi different clone preparations. 
1 0.97 mg/ml. 2 2.38 mg/ml, 
3 2.16 mg/ml. 4 3.67 mg/ml. 
5 1 pi uncut KS. 
The plasmid containing insert was cut v/ith Bbs I ready for use. Other controls were 
included for quality control of the final product before ligation with the prepared cDNAs. 
These controls included cutting with other restriction enzymes and the addition of ligase 
to prove the Bbs I cut vector with its non complementary ends did not religate. 
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1 2 3 45 6 7 8 9 10 11 12VIIII 1 2 3 45 6 7 8 9101I1213141516Vini 
Plate 9. Restriction of inserted vector Plate 10. Controls of prepared vector. 
to prepare for use and controls. 2 pi D N A markers V I & m . 
2 pi D N A molecular weight markers V I & III . 0^ ^^  "os- done 1; even nos. clone 2. 
1, 5 & 9: clone 1; 2, 6 & 10: clone 2; 
3, 7 & 11: clone 3; 4, 8 & 9: clone 4. 
1-4 PstlcuV, 5-8 Bbs I cut; 9-12 uncut. 
1 & 2 uncut circular vector with insert, 
3 & 4 Pvii I cut, cuts twice, 5 & 6 Pjf I cut, cuts once, 
I &&Bbsl cut, cuts once, 9 &10 Pst I cut + ligase. 
cuts and religates, concatamers, 
II & 12 Bbs I cut + ligase, cut once no religation, 
13 & 14 P5f I cut + ligase, Pvu I cut, cuts twice 
15 & 16 Bbs I cut + ligase, Pvii I cut, cuts twice 
The generation of the specific PCR products was titrated and observed for optimisation 
before concatamerisation occurred before proceeding with purification and preparation 
for cloning and subsequent ligation with vector. 
V I 1 2 3 4 5 6 7 8 9 V I 
Plate 11. Selective PCR of cDNA fragments prior to cloning. 
1 Mix, aa adaptor, c and a primers; 2 Liver, aa, cc, subset C B ; 3 M aa ga; 4 L aa gc, subset C E ; 5 L tt 
ca; 6 M tt cc, subset M; 7 L tt cc, subset C A ; 8 L tt ga, subset C D ; 9 L tt gc, subset C C . 
2 pi D N A molecular weight marker V I . 
After transformation, white colonies were picked and it was shown that over 75% of 
clones contained cDNAs between 340 and 750 bp (mostly 440-570 bp, average -500 
bp), and produced good clean PCR products suitable for further study. 
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3.2. Sequencing templates and data 
PCR reactions were observed before column purification of clean products to remove 
excess primers, and before bead binding. The Streptavidin bead wash of the eluted 
strand was also observed before proceeding with sequencing of the bead bound template 
strand. Only the clones that produced good PCR products were used for lacZ methods. 
I 2 3 4 5 6 7 8 9 10 11 1213 1415 1617 1819 20 21 222324 VI 
Plate 12. PCR products after column purification. 
1-24 5 pi samples of P C R products of different clones from plate C I O , subset CA. 
2 pi D N A molecular weight marker V I . 
Before using the lacZ method for purification the multiplicity of infection (m.o.i. phage 
to clone) to use for optimal growth had to be titrated: a sample of filtrate was always 
observed to check for good growth. It was found that a m.o.i. of ~x20, growing for 16 
hours using fresh colonies for inoculation gave the best results. 
1 2 3 4 5 6 7 8 9 10 11 12 VI I I I - > 2 3 ^ 5 6 \-\ m .. 
f . 9 9 ' f 
Plate 13. Titration of culture growth. 
1-3 No helper phage; 4-6 m.o.i. xlO; 7-9 m.o.i. x20, 
10-12 m.o.i. xlOO. 
1, 2, 4, 5, 7, 8, 10 & 11 grown in filtration plate; 
3, 6, 9 & 12 grown in bijou. 
D N A molecular weight markers V I & I I I . 
Plate 14. Growth of ssDNA. 
1-6 10 pi samples of filtrates. 
DNA molecular weight markers V I & I I I . 
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Filtering the cultures was compared with centrifugation, for removal of cells, and the 
subsequent purification using lacZ beads. Results obtained showed that the use of 
filtrates was better, although supematants were often used to produce good templates. 
1 2 3 4 V I m 1 \ a III 
Plate 15. Filtration compared 
to supernatant: growth. 
1 & 2 10 pi sample of filtrates; 
3 & 4 10 pi sample of supernatants. 
2 pi D N A markers V I & I I I . 
Plate 16. Filtration compared to supernatant: 
purified ssDNA. 
1 & 2 2 pi sample of purified elute from filtrates; 
3 & 4 2 pi sample of purified elute from supernatants. 
2 pi D N A molecular weight markers V I & HI. 
It was shown that about 600 pi of filtrate and 90 pi of beads produced enough purified 
ssDNA template (-500 ng) for sequencing. Beads could be reused, and home made 
beads appeared to produce acceptable templates. 
I I I ! 2 3 4 5 6 7 8 910 1U213141516VI I 2 3 4 5 6 7 8 9 10 11 1213 14 1516 17 18VIIII 
Plate 17. LacZ bead fitration. 
1-4 2 pi elute using 200 pi filtrate, 30 pi beads; 
5-8 2 pi elute using 400 pi filtrate, 60 pi beads; 
9-12 2 pi elute using 600 pi filtrate, 90 pi beads; 
13-16 2 pi elute using 800 pi filtrate, 120 pi beads. 
2 pi D N A markers V I & I I I . 
Plate 18. Evaluation of lacZ beads. 
1-6 2 pi elute using new beads; 
7-12 2 pi elute reusing beads; 
13-18 2 pi elute using customised beads; 
2 pi D N A markers VI & I I I . 
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V I 1 V I 1 2 3 4 5 6 
Plate 19. LacZ purified ssDNA. Plate 20. LacZ purified ssDNA. 
1-8 2 pi elutes using 600pl filtrate, 90pl beads, 1-6 2 pi elutes using 600 pi filtrate, 90 pi beads, 
clones from plate C7 (subset C A ) . clones from plate C 7 (subset C A ) . 
2 pi D N A molecular weight marker V I . 2 i^l DNA molecular weight marker V I . 
In total over 2000 ssDNA templates were produced by these two methods. The number 
of Ns (ambiguities called) between base 50 and 400 in the sequence was counted 
automatically by a small Unix program CDtotal, which only accepted the sequence into 
"good" i f there was <14 Ns (4%) ambiguity. 
There was some degree of artificial wastage due to experimentation with terminator 
clean up methods. It was found that a column alone was sufficient to clean reactions if 
the template was prepared by lacZ methods, but a phenol/chloroform purification and 
column (or two phenol chloroform purifications) was required for the Streptavidin 
templates, otherwise fluorescent artefacts were observed in the gel. Much variation was 
seen in the yield and purities eluted off the various columns tested: many parameters 
including buffer used and centrifugation speeds had a profound effect. Triethyl 
ammonium acetate (TEAA) was found to be one of the best buffers for use. Yields of 
sequencing products were sometimes low if purification procedures were not done to 
specification. 
A total of 1552 "good" ESTs were generated, sequencing some clones in both 
directions. While using "Sedit" to cut pieces of vector and ambiguities from the 
sequences, Bluescript and adaptor sequences were often found at the beginning of the 
sequences, but ambiguities were normally the limiting factor at the end. 
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Preliminary investigations show that the ligation and PCR selected bases in each subset 
are seen in most cases. Where the start of the sequences are recognised, Fok I sites have 
been searched for: initial figures suggest cutting sites are seen in under the expected 50% 
of sequences at the expected position after the adaptor sequence at the start. 
In general a high proportion of the ssDNA templates produced high quality fluorescent 
signals of EST data with low background impurities and ambiguity. 
F i n a l 
CA 
Nuniber of good f o r CA.FOR: 3 03 
Number of good f o r CA.REV: 34 5 
Average of length: 677.41 
Average of number of N: 6.78 
CB 
Nun±)er of good f o r CB.FOR: 234 
Number of good f o r CB.REV: 88 
Average of lengt:h: 645.18 
Average of nuinber of N: 5.97 
CC 
Nun±>er of good f o r CC.FOR: 4 2 
Nun±>er of good f o r CC.REV: 62 
Average of length: 600.30 
Average of number of N: 6.49 
CD 
Number of good f o r CD.FOR: 66 
Nuntber of good f o r CD.REV: 64 
Average of length: 784.35 
Average of number of N: 5.55 
CE 
Number of good f o r CE.FOR: 67 
Nuniber of good f o r CE.REV: 3 7 
Average of length: 753.02 
Average of nun±ier of N: 8.92 
M 
Number of good f o r M.FOR: 152 
Number of good f o r M.REV: 90 
Average of length: 715.28 
Average of number of N: 7.45 
Number of good: 1552 
Figure 10. Final: The output produced in Unix by the program CDtotal. 
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Model 373A 
Verakm 1.2.0 
Sample 20 
DyeTeni*ialor<AnyPnn»r) 
Uine20 
Signal: G:1120 A:965 T:537 CSAO 
Poinis 715 to 6600 Base 1:715 
900 Insmimert Hie 
026611 FOR 
LACZ 
Wed, Dec 22,1993 5:38 PM Page 1 ol 1 
X:0lo7375 Y:0lo1200 
Spadng: 10.31 
k:,\C GGCC •. i f . iAgCAaOOTTT^TOQAQ T C A ^ y I C A T O T C T ^ T ACAT A A(J^^TCCCAT A A , ^ A T O T C A a q g p C I C C C ^ C ( ^ g A T AQOCC A ^ A O I T TQ TtjgJCACTGAOT^jgQCA « * A^JJBC' 
an . I i ' I > n i n i i II in n (1 
m 
QCi Q T ^ j p C T Q C C * T T ^ J T C I Q Q T Q ^ Q O C A T i ; A l | ^ C C X » C O A ^ g J C A O C T G O q | g ^ T T T C T T ^ T Q ^ 
1 
fclCaK^rOQCAATf^TCGICTTtJ^JflBATOT T ^ C T T T TAATgJCTC O G A C ^ J ^ I CCOa^^OCTTA TCOjyWaWCGACpjCOQAGOGGJjgQCCGGGA Cgg AG T r r m ^ g C C C T TI AHf^9»OQGI 
feTAA^OQOCCIWggllAACAAIK^IIQIITQGr ^ M H Q A A T ^ T T C C M T a ^ A T C C C A A ^ A A C O A C C C ( J | | A I I A A M I T T ^ C C O Q e O C | j ( ^ THAT I I A T ^ ^ A A T A I 
Figure 11. Automatic sequencer output for clone C25E11 (subset CE). 
L a c Z template, forward primer & terminator sequencing. 
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Model 373A 
Verakm 1.2.0 
Sainiile 12 
DyeTerminatoftAnyPrimer} 
Line 12 
Signal: G:571 A:306T:237Ca05 
Points 640 to 6400 Base1:640 
900 Instnjitient RIe 
C21F2 
S K S 
Wsd, NOV 17, 1983 SOTPM PaQ6 1 o( 1 
X:0lo7176 Y:0lo1200 
Spadng: 10.55 
U T N G Q Q C e ^ Q « C A C l g T C C G B O > « Q ^ A I « C T G C j | p Q r C A T T C C ^ T G C A a Q a ^ C e G C C O A O ^ ; ^ C C A O C T g p C M Q * * T C j ^ r C T T 
i 
r C C T T C C T C T T C T T Q Q O G X A Q M A C A O C C ^ C O Q G A C T i ^ - ^ O O O A T r A i ^ T Q G G C l C ' ^ T T C C T G C T J ^ C A G O B O i y j A T T C A C C T ^ Q T C AOIICjygOTO * * G * - ^ * G CC" ATOCCq 
P ^ C C C T Q G G ^ ^ C C A C T O T ^ g O ^ ^ 
k l T t l ^ C A T A G r T q g T G T G G A C t J ^ J A T A O G A C T ^ A T Q O T r A T g J T C C A T T i q g ^ T T T O T O A I ^ A O A A A M T C j y i A T C A QTA JJ^ TOT T T T C T ^ T A A S O T O ^ M U T C T A N A Q »**(jf;^ 
A q g ^ ; G T Q G K ^ a T T a A i n T ^ C n : T N T M q | J ^ C C C T C C A ^ ^ A a a G T C ^ - ^ T T C r Q a A I ^ W T C C q j ^ T H G O A T Q Q ^ A C D M T A | ^ | N A A A A M 
Figure 12. Automatic sequencer output for clone C21F02 (subset CC). 
P C R streptavidin template, K S primer & terminator sequencing. 
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Model 373A 
Vareion 1.2.0 
Sample 16 
DyBPrimer(-21m13> 
Lane 16 
Signal: C:103 A^OO 0:158 T:96 
Points 798 to 5900 Base1:79e 
900 Instniment File 
C8C10 
600 90T 
Wed, May 5, 1993 loa) AM Page 1 ol 1 
X:0to5928 Y:0to1200 
Spacing: 11.12 
BIOITAAI AffiACTCACT ^AOaGOOAATJjQGAOCl CCAgjCQCGGTGW^AC C G C T C T AfiAACT AQTOQ/ | jCCaaCTCG^GTGt TCTOtaAGCAC T G T C C W G A C T T I T ^ y TOAGATa<UaTTTC< 
C C C | y Q T T a C C C A ^ g C T Q Q A Q Q ( ^ A T G Q C C T G ^ T T C C Q C T C ^ g T O C A A C C T ^ Q C C T C C T C ^ T T C A A Q C A ^ T C T C C T G ( ^ J C A Q C C I C C ^ A G T A 0 C - Q g y A T T A C A O ^ T Q C A C C A Q g ^ T a 
r C T G G t ^ A T T T G Q T ^ T I T A G T A ( ^ ^ T G G G a T T ^ C C A T G T ( ^ g p C C A G Q C T < ^ C T T G A A C ^ T G A C C T C A ^ T C C e C T ( ^ g C T T Q Q C T T ^ T C T C C r q g ^ 
p T T A g j ^ T A C C G T C g g C C T C G A G ^ f ^ g G a i l l C C C ^ A C C C A G C r ^ T G T T C O C ^ T A G T G M K ^ T A M T l l i q j g G T n Q Q G T ^ T B A I i G G T ^ A Q C T N T TJgJGGmilAA.yyT T AATCCt^^jA AA 
Figure 13. Automatic sequencer output for clone C08C10 (subset CA). 
L a c Z template, forward primer & primer sequencing. 
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JL^AffllKl Saiiipte23 Poirts650to6000 Base1:650 Mon, Jan24,1994 7:11 PM Page1o(2 
^ M O t o q A i m DyoTeni»nalo4<AnyPnm«) 900InstnjmenI Flo X:0to6677 Y:0to 1200 
Model 373A Lane 23 C10H4FORLACZ Spacing: 10.42 
Vereion 1.2.0 Signal: G:490 A305 TaOS C:89 PC BIO 
k A C A A Q j ^ G A Q T T T O T ^ y C T T G A T T T ^ C T C T C C T T ^ C A Q A A A Q T ^ O C A T A T A T j y O C A T G G A j y j ^ T O A A T O T T j y g A O C A T T A ^ ^ T C T T T G a Q ^ ^ T A T O T T ^ A T C O A C C ' ^ A ^ 
aACTXTOTCACT TteTGOWOTa i m C A TGCA « ^ C A TA/C^TTCA^e^ggACOQAT AI^JAGTCTTCT^ACA A ^ AGH A I G G T ^ ^ C T Q T T & y g A MGQ AT TGCAO A A T 
t j T C T T r T r ^ J T C A O O A l ^ ^ A C A A O A l ^ 
Figure 14. Automatic sequencer output for clone C10H04 (subset CA). 
LacZ template, forward primer & terminator sequencing. 
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Model 373A 
Vorekxi 1.2.0 
SaiTipte14 
Dy9Pnnier(-21m13) 
Lane 14 
agnel: C:138 A:78 G:60 T:44 
Paints 792 to 6000 Base1:792 Wed. May 5, 1993 10t» AM Page t ol 2 
aaOlnakunient Fie X:0toe057 Y:Oto 1200 
C8810 Spacing: 11.14 
600 SOT 
AT l a a y a C T C T O Q C W Q ^ A M a a A C T T ^ T Q T M I A O A A j ^ T G C T Q C A M ^ T Q A C a A T A ^ a A Q A C C T a j ^ ^ T G C C G A Q ^ G O Q I A A A A ^ C T TH T TOC1 
» W « T C A > y O C T « C T T A M C T T A T A A C A j ( g A C * T T T A A ^ a C A T C T C < ^ ^ T A C C A T ^ A A T A A a A < ^ A O A A A A I < ^ J O A I C A A A A g g T T A T T C A ^ 
^ A C C C T Q T t ^ - ^ A A A A A C A T ^ A T T T C T T T ^ T C A T T T T ^ T C T T T T C ^ j a T f l C T I C A ^ T AQTAAA^TOOAAAa^C TAB A AA AjJgAaTCTCGI|Jg AOI HT i r r j | | M W T ia r j | |A '«Ca l 
tyigCCTCQTQqggar-aCOCQ^yCCCTQC T T ^ y G T B C C O I T ^ A O r a O Q i J ^ J A A T l I I C a C ^ TTQGGTBA^ATGQGa A T ^ T M T T C C I j y W W A A A I J J T I l n W G ^ J ^ C A T T T C W i j ^ g * 
Figure 15. Automatic sequencer output for clone C08B10 (subset CA). 
LacZ template, forward primer & primer sequencing. 
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3.3. A n a l y s i s o f d a t a 
The 1552 "clean finished good" ESTs were put into the cDNA database: using BLAST 
they were compared with the sequences in the public databases for similarities, 
(GenBank November 1993 release contained 217 377 sequences and 219 858 629 total 
letters). Many significant similarities over 95% were obtained: the matches of 98-100% 
show the general quality of sequencing was very high. 
Reiu lcs of Databisse Search 
Labocacocy : HGM?-?.C 
L i b r a r y : CE 
Plate : 25 
Pos i t ion : E l l 
Soecies : KUM.I 
Tissue : L i v e r 
D irec t ion : forward 
Sequence : GaOAC.»TATa7TTC.\7CC.^CCii.CC.iAGCTaCTC.».V3CATGGCCTCCT3TT 
GaCATATa.\.\3.\.\3T3C.=iGCACTaGCCA.\C.!iCCAC-3GTTTACTGG.s.C-T:.\ 
TTTCA-GTCTGATACATAAGTOTCCG.ATAATAA-GTCAGCCGC-CCCTCG 
CC.\T.AGGCCA^.TAGTTTATCCTCACTGAGTTGCCAACAA0TGGCTC-:T3T 
• GGCTACCA':-TTTCTGGTGATGGCCATCCAGC7CCGACGAGGTCAJ:-:3G 
GGGGN'TTTCTTTTG-GTAA3CAACG.AGA.AACGC.ATTTTGGGAGT.AATATT 
CTCCTAGTT7CT7GG.\.\GGAGGCCGCAGNTTCC3TTTTGGCAATGCT-3G 
TCTCCTGGATGTTTT7CTTG-A.\TGTCTCGGA.VAAGGMTCCCGAJ.-.3:TT 
ATCGTCCCMMCG.^CCCCGAGGGGGGCCGGGNCCC.AGTTTTGGTCCCCTTA 
N:;3.V3GG-A-A.ATGGGGNTGGGGMACAAGGCA::CH-:GGTCCHGM::T:;.IATC 
G.ATCCTC.Y.'A~CCCA_V.I.A.AACA.ACCGG«G.WL;;:::;TAAGCCGGGGC-ATM 
A7^ 'ATATCAA,^ TATGGG^ .*GGGCAT^ •^CCTTCNGCGGAACCM^ G^GCr-.*T:.^ AT 
A7A-7GC.ACCG-3MG0GGGGG7TGGMCN-CCMCCCCCATCTCCC 
Figure 16. Sequence of C25E11, AAAFRGR. 
Results o£ Database Search 
The fol lowing best ir.a tches a re found for your requested sequence 
Seqid Database Pe rcent Matching Le.igth Descript ion 
AAATRG.^  ge.-.ban'x 93 227 223 huraan mrna encoding alpha-fetoprotein (afp) 
AAAJRGR genbank 99 227 223 human alpha-fetoprotein (afp) mrna, complet 
AAATRGR genbank 100 141 141 human alpha-fetoprotein 9e.ie, complete cds. 
AAATRGR ge.Tbank 99 HO 141 g o r i l l a alpha-fetoproteir. (afp) gene, conpl 
AAATRGR genbar.k 71 15'4 223 mouse mrna encoding alpha-fetoprotein (a te 
AAAJ.^ GR genbank 70 150 223 rat a lpha-fetoprotein err.a ( p a r t i a l ) . 
AAAiRGR genbank 70 loO 223 rat messenger rna coding for alpha-fetoprot 
AAAFRGR genbank 70 150 223 rat mrna for alpha-fetcpratein (afp) (this 
A.AA-.RGR genbank 75 105 141 mouse alpha-fetoorotein (afp) gene, exon 12 
AAAFRGR genbenk 73 10 5 149 rat a lpha-fetoprotein 3-?rime e n d n r n a . 
AAArRGR genbank 73 105 149 messe.nger r.-.a for rat a l .ha- fetoprote in . 
AAATRGR swissprot 93 74 75 alpha-fetoprotein precursor (alpha-fetoglot 
A-A-ATRGR swissprot 93 74 75 alpha-fetoprotein precursor (alpha-fetoglot 
A.AArR3R swissprot 54 43 83 alpha-fetoprotein precursjr (alpha-fetoglot 
AAAFRGR swissprot 52 45 87 alpha-tetoprotein precursor (alpha-fetoglot 
AAAfRGR swissprot 43 35 83 seru.-n albu.-Tiin precursor . 
AAArRGR swissprot 43 31 72 seru.n albumin precursor (fragment) . 
AA . \ rRCR swissprot 43 3: 73 seru.tv albumin precursor . 
A-AATRGR swissprot 33 34 83 serum albumin precursor . 
AAArRGR swissprot 37 33 83 serum albumin precursor . 
AA.\rRGR swissprot 42 31 73 serum albumin precursor . 
AAATRGR swissprot 45 3: 71 serum albumin precursor . 
A.\ArRGR cdna matches to other cDNA's in the database. 
23 entr i e s i n the da tabase matched the searc h request. 
Figure 17. The listed BLAST matches of AAAFRGR. 
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R e s u l t s of Database Search 
AAAFRGR genbank 
> HSFETO V01514 Human mRNA encoding a l p h a - f e t o p r o t e i n (AF?). AFP i s a major 
serum p r o t e i n (MG: 70000) synthesized during f e t a l l i f e . 
Length = 2029 
Minus Strand HSPs: 
Score = 1131 (312.S b i t s ) , Expect = 9.1e-87, P = 9.1e-S7 
I d e n t i t i e s = 227/223 (99%) , P o s i t i v e s = 227/228 (99%), Strand = Minus 
Query: 22S 
S b j c t : 1385 
Query: 168 
S b j c t : 1445 
Query: 108 
S b j c t : 1505 
Query: 43 
S b j c t : 1565 
Score = 253 
I d e n t i t i e s 
Query: 316 
S b j c t : 1299 
Query: 256 
S b j c t : 1359 
GATGGC 
CAAACl 
:GA<LMAGCGGCTGA( 
iAACCCTGGTGTTGGC 
UUVCCCTGGTGTTGGC 
lAGCTTGGTGGTGGA'j 
l l l l l l l l l l l l l l l l l l l l l l l l 
:CACTTGTTGCCAACTCAGTGAGGA 
TATTATCGGACACTTATGTATCAG 
l l l l l l l l l l l l l l l l l l l l l l l l 
TATTATCGGACACTTATGTATCAG 
LGTGCTGCACTTCTTCATATGCCAA 
l l l l l l l l l l l l l l l l l l l l l l l l 
iGTGCTGCACTTCTTCATATGCCAA 
AACATATGTCCC 1 
l l l l l l l l l l l l 
kAACATATGTCCC 1612 
ion P(2) = 9.0e-29 
> HUMALBAF4 J00077 Human alph a - f e t o p r o t e i n (AFP) mRNA, complete cds. 
Length = 2032 
Minus Strand HSPs: 
Score = 1131 (312.5 b i t s ) . Expect = 9.1e-87, P = 9.1e-87 
I d e n t i t i e s = 227/223 (99%), P o s i t i v e s = 227/223 (99%), Strand = Minus 
Query: 228 
S b j c t : 1383 
Query: 168 
S b j c t : 1443 
Query: 108 
S b j c f : 1503 
Query: 43 
S b j c t : 1568 
l l l l l l l l l l l l l l l l l l 
GATGGCCATCACCAGAAAi 
CAAACTATTGGCCTATGGt 
l l l l l l l l l l l l l l I I I 
CAAACTATTGGCCTGTGG( 
ACATGAAATGACTCCAGTi 
I I M I I I I I I I I I I I I I I 
ACATGAAATGACTCCAGT, 
CAGGAGGCCATGCTTCAGi 
I I I I I I I I I I I I M I I I I 
l l l l l l l l l l l l l l l l l l l l l l l l I l l l l l l l l l l l l l l 
:GGCAGCCACAGCAGCCACTTGTTGCCAACTCAGTGAGGA 
LGGGAGCGGCTGACATTATTATCGGACACTTATGTATCAG 
l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l 
VGGGAGCGGCTGACATTATTATCGGACACTTATGTATCAG IICCCTGGTGTTGGCCAGTGCTGCACTTCTTCATATGCCAA 
l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l 
VCCCTGGTGTTGGCCAGTGCTGCACTTCTTCATATGCCAA 
SCTTGGTGGTGGATGAAACATATGTCCC 1 
l l l l l l l l l l l l l l l l l l l l l l l l l l l l 
Figure 18. The best BLAST matches for AAAFRGR. 
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R e s u l t s of Database Search 
Detaiils of request AAAFAYS 
Laboratory 
L i b r a r y 
P l a t e 
P o s i t i o n 
Species 
T i s s u e 
D i r e c t i o n 
Sequence 
HGMP-RC 
C C 
21 
F02 
Human 
L i v e r 
r e v e r s e 
ATTTAGNGCGTCGGAGCACTGTCCGGGACGAAATACCTGCTGGTCATTCC 
CATGCAGGGNACCGGCCGAGTAGCCCAGCTGGCAGGAATCTTCTTTCTTG 
GTGACTTCAGTTACCAGTTGCCCACCCCCTGATCCTTCCTCTTCTTGGGG 
TAGNACAGCCCTCCGGACTCTCGGGATTAAGATGGGCTCTGGTTCCTGCT 
CCCCAGGGGNACATTCACCTCGGTCAGCCATGGTGAAGATGGAGTCCTCA 
GGGATGCCCACACCCTGGGCAACCACTCTGAAGTCCTGCAGGAGAGTTTC 
CCTCAGCTGNGGCGCCCGCCCGTAGAGCTTGGCAGTAATGGTGGGTCCAT 
GATGGCGGGTGAATTTCTTGGTCAGGA.AAATGGCATACTCATCATAGTTG 
GGTGTGGACCACATAGGACTCCATGGTTATGTTCCATTTGGATTTGTGAT-
AGAGAAANTCCCATCAGTATCTTGTTTCTCATAAGGTCCAGANGTCTTCT 
CANAGAAACCTTCCGGCAACGAGTGTGGTCAAGTTGATTTCCGCTCTNTG 
GGGCCCTCCAGAACAGGGTCTTCTCTGGGANAGTCAATCGCNNTGGGATN 
GTTAGGGGT 
Figure 19. Sequence of C21F02, AAAFAYS. 
R e s u l t s of Database Search 
The f o l l o w i n g best matches are found for your requested sequence 
Seqid Database Percent Matching Length D e s c r i p t i o n 
AAAFAYS genbank 98 338 344 human mrna f o r alpha-l-raicroglobulin and 
AAAFAYS genbank 93 333 344 human mrna f o r protein he (alpha-l-microc 
AAAFAYS genbank 83 280 334 porcine mrna f o r alpha-1 microglobulin/hi 
AAAFAYS genbank 33 230 334 porcine mrna f o r alphal-microglobulin-bik 
AAAFAYS genbank 79 280 354 mesocricetus auratus rama f o r precursor c 
AAAFAYS genbank 69 337 433 polyprotein 1-microglobulin/bikunin [ r a t s 
AAAFAYS genbank 69 323 472 meriones unguiculacus mrna f o r precursor 
AAAFAYS genbank 67 319 472 m.musculus ambp mma for alpha-1-microglc 
AAAFAYS genbank . 97 105 109 (repeat region: alu) human gene for alpha 
AAAFAYS genbank 97 106 109 human i n t e r - a l p h a - t r y p s i n i n h i b i t o r l i g h t 
AAAFAYS genbank 77 123 165 r a t alpha-l-microglobulin mma. 
AAAFAYS s w i s s p r o t 77 127 164 alpha-l-microglobulin / i n t e r - a l p h a - t r y p s 
AAAFAYS s w i s s p r o t 64 105 164 alpha-l-microglobulin / i n t e r - a l p h a - t r y p s 
AAAFAYS s w i s s p r o t 35 29 80 alpha-l-microglobulin / i n t e r - a l p h a - t r y p s 
AAAFAYS s w i s s p r o t 23 20 59 prostaglandin-h2 d-isomerase precursor (e 
AAAFAYS s w i s s p r o t 36 16 44 von ebners gland protein precursor (veg p 
AAAFAYS s w i s s p r o t 55 14 25 i n t e r - a l p h a - t r y p s i n i n h i b i t o r ( i t i ) ( e i - 1 
AAAFAYS s w i s s p r o t 33 9 27 progesterone receptor (pr) (forms a and t 
AAAFAYS s w i s s p r o t 51 16 31 gooseberry d i s t a l protein (bsh9). 
AAAFAYS s w i s s p r o t 55 10 18 major centromere aucoantigen b (centromer 
AAAFAYS s w i s s p r o t 31 13 57 immediate-early protein ie68 (orf4) (frag 
AAAFAYS s w i s s p r o t 39 11 28 phosphoenolpyruvate carboxykinase, mitoch 
AAAFAYS cdna matches to other cDNA's i n the database. 
23 e n t r i e s i n . the database matched the search request. 
Figure 20. The listed BLAST matches of AAAFAYS. 
62 
BLASTN 1.3.12 t29-OcC-931 [ B u i l d 15:48:47 Nov 25 1993] 
Reference: A l e s c h u l , Stephen F., Warren Gish, Webb M i l l e r , Eugene W. Myers, 
cind David J . Lipman (1990). B a s i c l o c a l alignment search t o o l . J . Mol. B i o l . 
215:403-410. 
Notice: t h i s program i s optimized to f i n d n e a r l y i d e n t i c a l ssq-jences r a p i d l y . 
To i d e n t i f y wea)c s i m i l a r i t i e s encoded i n n u c l e i c a c i d , use BLASTX or TBLASTN. 
Query= CC-21-F02.REV.SEQ.comp, 609 bases, 4EC52932 checksum. 
(609 l e t t e r s , both strands) 
Database: genbank 
217,377 sequences; 219,858,629 t o t a l l e t t e r s . 
Searching do.^ .e 
Smallest 
Poisson 
Sequences producing High-scoring Segment P a i r s : 
HSAIMICR X04494 Huraan mRNA f o r alpha-l-microglobulin an. 
HSHCR X04225 Human mRNA f o r p r o t e i n HC (alpha-l-micr. 
SSAMGBIK X53685 Porcine mRNA for alphal-microglobulin-b. 
SSAMHI30 X52087 Porcine mRNA for alpha-1 microglobulin/. 
HAMPCFTB D31814 Mesocricetus auratus mRNA for precursor. 
S37544 S87544 p o l y p r o t e i n 1-microglobulin/bikunin [ r a . 
MUIPCFTA D31813 Meriones unguiculatus mRNA fo r precurso. 
MMAMBP XS8680 M.musculus AMBP mRNA f o r alpha-1-microg. 
HSAIMBGI X54816 Huraan gene f o r al p h a - l - m i c r o g l o b u l i n - b i . 
HUMITILC05 M88246 Human i n t e r - a l p h a - t r y p s i n i n h i b i t o r l i g . 
RATMGBA J02600 Rat al p h a - l - m i c r o g l o b u l i n mRNA. 
HSAIMBG3 X54818 Human gene f o r al p h a - l - m i c r o g l o b u l i n - b i . 
HUMITILCOS M88249 Human i n t e r - a l p h a - t r y p s i n i n h i b i t o r l i g . 
HUMITIL,C04 M8a245 Human i n t e r - a l p h a - t r y p s i n i n h i b i t o r l i g . 
HSA1MBG2 X54817 Huraan gene f o r alpha-l-microglobulin an. 
HOMITILC05 M88247 Human i n t e r - a l p h a - t r y p s i n i n h i b i t o r l i g . 
SMOSPAl L25598 Salmo s a l a r alpha-l-microglobulin/bikun. 
HUMITILC03 M88244 Human i n t e r - a l p h a - t r y p s i n i n h i b i t o r l i g . 
High P r o b a b i l i t y 
Score P(N) - N 
1656 1 le-131 1 
1656 1 le-131 1 
1184 2 6e-91 1 
1184 2 6e-91 1 
1104 3 8e-84 1 
1101 9 5e-84 1 
1054 6 le-80 1 
983 9 9e-73 1 
518 2 7e-51 2 
518 2 4e-33 1 
492 3 6e-33 1 
408 6 3e-24 1 
408 6 4e-24 1 
401 9 4e-24 1 
248 1 3e-10 1 
238 7 Oe-10 1 
221 2 7e-08 1 
210 2 le-07 X 
>HSA1MICR X04494 Human mRNA f o r alpha-l-microglobulin and HI-30. 
Length = 1221 
Plus Strand HSPs: 
Score = 1665 (450.3 b i t s ) . Expect = 1.le-131, P = 1.le-131 
I d e n t i t i e s = 338/344 (98%), P o s i t i v e s = 338/344 (93%), Strand = Plus 
Query 
S b j c t 
Query 
S b j c t 
Query 
S b j c t 
Query 
S b j c t 
209 CCAACTATGATGAGTATGCCATTTTCCTGACC:AAGAAATTCACCCGCCJVTCATGGACCCA 268 
M I I I I I I I I I I I I I I I I I I I I I I I I M I I I I I I I I I I I I I I l l l l l l l l l l l l l l l l ' l 
419 CCAACTATGATGAGTATGCCATTTTCCTGACCAAGAAATTCAGCCGCCATCATGGACCCA 478 
269 CCATTACTGCCAAGCTCTACGGGCGGGCGCCNCAGCTGAGGGAAACTCTCCTGCAGGA(rr 328 
I I I I I I I I I I I I I I M I I I I I I I I I I I I I I I l l l l l l l l l l l l l l l l l l l l l l l l l l l l 479 CCATTACTGCCAAGCTCTACGGGCGGGCGCCGCAGCTGAGGGAAACTCrrCCTGCAGGACT 538 
329 TCAGAGTGGTTGCCCAGGGTGTGGGCATCCCTGAGGACTCCATCrrTCACCATGGCTGACC 3 88 
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I M I I I I I I I I I I I I I I 53 9 TCAGAGTGGTTGCCCAGGGTGTGGGCATCCCTGAGGACTCCATCTTCACCATGGCTGACC 5 98 
389 GAGGTGAATGTNCCCCTGGGGAGCAGGAACCAGAGCCCATCTTAATCCCGAGAGTCCGGA 44 8 
l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l 59 9 GAGGTGAATGTGTCCCTGGGGAGCAGGAACCAGAGCCCATCTTAATCCCG.\GAGTCCGGA 6 58 
Query: 4 4 9 GGGCTGTNCTACCCCAAGAAGAGGAAGGATCAGGGGGTGGGCAACTGG7AACTGAAGTCA 5 0 8 
I I I M I I l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l 
S b j c t : 5 5 9 GGGCTGTGCTACCCCAAGAAGAGGAAGGATCAGGGGGTGGGCAACTGGTAACrrGAAGTCA 7 1 8 
Query; 5 0 9 CCAAGAAAGAAGATTCCTGCCAGCTGGGCTACTCGGCCGGTNCC 5 5 2 
I I M I I I M I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I II 
S b j c t : 7 1 9 CC:AAGAAAGAAGATTCCTGCCAGCTGGGCTACTCGGCCGGTCCC 7 6 2 
Figure 21. The listed and best BLAST match for AAAFAYS. 
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R e s u l t s of Database Search 
D e t a i l s of request AAAFJAU 
Laboratory 
L i b r a r y 
P l a t e 
P o s i t i o n 
Species 
T i s s u e 
D i r e c t i o n . 
Sequence 
HGMP-RC 
CA 
8 
CIO 
Human 
L i v e r 
forward 
CAAGCTGCGAAATCATCCATAACAGCTTTCAGTTGCTNTTTTGTTGCCTT 
GGGCTTGTGTTTCACAAGNTCAACAAGTGCAGTTTGTTTCTTGATTTGTC 
TCTCCTTCTCAGAAAGTGTGCATATATCTGCATGGA.^GGTGAATGTCTCA 
GCATTAAACTCTTTGGGAACGTATGTTTCATCGACTTCO.GAGCTGAAAA 
GCATGGTCGCCTGTTCACCAAGGATTCTGTGCAGCATTTGGTGACTCTGT 
CNTNTACTGGCGTTTTCTCATGCAACACACATAACTGGCTCAGGACCACG 
GATAGATAGTCTTCTGCACAGGGCATTCTTTTTGCTTCAGGATGTTTACA 
ACATTTNGTC 
Figure 22. Sequence of C08B10, AAAFJAU. 
R e s u l t s of Database Search 
The f o l l o w i n g b e s t matches are found f o r your requested sequence 
Seqid Database Percent Matching Length Description 
AAAFJAU genbank 98 343 355 sequence 1 from patent us 4 914027. 
AAAFJAU genbank 98 348 355 h.sapiens (pxl53) gene for serum albumin. 
AAAFJAU genbank 93 348 355 h.sapiens (pxl53) gene for serum albumin 
AAAFJAU genbank 93 348 355 a r t i f i c i a l sequence for the pr o t e i n f u s i o 
AAAFJAU genbank 97 345 355 human serum albumin. 
AAAFJAU genbank 97 346 355 human messenger m a for serum albumin (hs 
AAAFJAU genbank 97 345 355 h.sapiens mma for serum albumin. 
AAAFJAU genbank 97 345 355 human serum albumin (alb) mma, complete 
AAAFJAU genbank 97 346 355 h.sapiens mma f o r albumin. 
AAAFJAU genbank 97 335 342 a r t i f i c i a l sequence for human serum album 
AAAFJAU genbank 92 330 357 macaca mulatta serum albumin mma, 3 end. 
AAAFJAU s w i s s p r o t 95 114 119 serum albumin precursor. 
AAAFJAU s w i s s p r o t 77 91 118 serum albumin precursor. 
AAAFJAU s w i s s p r o t 73 87 119 serum albumin precursor. 
AAAFJAU sw i s s p r o t 73 87 119 serum albumin precursor. 
AAAFJAU sw i s s p r o t 69 33 119 serum albumin precursor. 
AAAFJAU s w i s s p r o t 72 85 119 serum albumin precursor (fragment). 
AAAFJAU s w i s s p r o t 42 51 119 serum albumin precursor. 
AAAFJAU s w i s s p r o t 47 55 116 alpha-fetoprotein precursor (alpha-fetogl 
AAAFJAU s w i s s p r o t 45 54 116 alpha-fetoprotein precursor (alpha-fetogl 
AAAFJAU sw i s s p r o t 40 47 115 alpha-fetoprotein precursor (alpha-fetogl 
AAAFJAU s w i s s p r o t 41 48 115 74 kd serum albumin precursor. 
AAAFJAU cdna matches to other cDNA's i n the database. 
23 e n t r i e s i n the database matched the sear c h request. 
Figure 23. The listed BLAST matches of AAAFJAU. 
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R e s u l t s of Database Search 
AAAFJAU genbank 
> 101999 101999 Sequence 1 from patent US 4914027. 
Length = 1880 
Minus Strand HSPs: 
Score = 1712 (473.1 b i t s ) . Expect = 3.1e-135, P = 3.1e-135 
I d e n t i t i e s = 348/355 (98%), P o s i t i v e s = 343/355 (93%), Strand = Minus 
i i i i i M i i i i i i i i i i M i i M i i i i i i i i i i i i i i i i i i i i r i i i i r M i m i i i i i 
AAATGTTGTAAACATCCTGAAGCAAAAAGAATGCCCTGTGC\GAAGACTATCTATCCGTG 
GTCCTGAGCCAGTTATGTGTGTTGCATGAGAAAACGCCAGTANANGACAGAGTCACCAAA 
I I M I I I I I I I I I I I I M I I I I I I . I I I I I I I I I I I I I I I I I l l l l l l l l l l l l l l l 
GTCCTGAACCAGTTATGTGTGTTGCATGAGAAAACGCCAGTAAGTGACAGAGTCACCAAA 
TGCTGCACAGAATCCTTGGTGAACAGGCGACCATGCTTTTCAGCTCTGGAAGTCGATGAA 
l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l 
TGCTGCACAGAATCCTTGGTGAACAGGCGACCATGCTTTTCAGCTCTGGAAGTCGATGAA 
ACATACGTTCCCAAAGAGTTTAATGCTGAGACATTCACCTTCCATGCAGATATATGCACA 
l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l 
ACATACGTTCCCAAAGAGTTTAATGCTGAAACATTCACCTTCCATGCAGATATATGCACA 
CTTTCTGAGAAGGAGAGACAAATCAAGAAACAAACTGCACTTGTTGANCTTGTGAAACAC 
M I I I I I I I I I I I I I I I I I I I I I I M I M I I I I I I I I I I i l l l l l l l l l l l l l l l l l l l 
CTTTCTGAGAAGGAGAGACAAATCAAGAAACAAACTGCACTTGTTGAGCTTGTGA^JLCAC 
AAGCCCAAGGCAACAAAANAGCAACTGAAAGCTGTTATGGATGATTTCGCAGCTT 2 
l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l 
> A037S3 A03758 H.sapiens (pXL53) gene for serum albumin. 
Length = 2135 
Minus Strand HSPs: 
Score = 1712 (473.1 b i t s ) . Expect = 3.5e-135, P = 3.5e-135 
I d e n t i t i e s = 348/355 (93%), P o s i t i v e s = 348/355 (98%), Strand = Minus 
l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l 
AAATGTTGTAAACATCCTGAAGCAAAAAGAATGCCCTGTGCAGAAGACTATCTATCCGTG 
GTCCTGAGCCAGTTATGTGTGTTGCATGAGAAAACGCCAGTANANGACAGAGTCACCAAA 
I I M I I I l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l 
GTCCTGAACCAGTTATGTGTGTTGCATGAGAAAACGCCAGTAAGTGACAGAGTCACCAAA 
TGCTGCACAGAATCCTTGGTGAACAGGCGACCATGCTTTTCAGCTCTGGAAGTCGATGAA 
M ' l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l 
TGCTGCACAGAATCCTTGGTGAACAGGCGACCATGCTTTTCAGCTCTGGAAGTCGATGAA 
ACATACGTTCCCAAAGAGTTTAATGCTGAGACATTCACCTTCCATGCAGATATATGCACA 
I M I I I I I I I I I I I I I I I I I I I I I I I I I M I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
ACATACGTTCCCAAAGAGTTTAATGCTGAAACATTCACCTTCCATGCAGATATATGCACA 
CTTTCTGAGAAGGAGAGACAAATCAAGAAACAAACTGCACTTGTTGANCTTGTGAA.ACAC 
l l l l l l l l l l l l l l l l l l l l l l l l l l l l l i l l l l l l l l l l l l l l l l M I I I I I I I I I I I 
Query: 355 
S b j c t : 1419 
Query: 295 
S b j c t : 1479 
Query: 236 
S b j c t : 1539 
Query: 176 
S b j c t : 1599 
Query: 116 
S b j c t : 1559 
Query: 55 
S b j c t : 1719 
Query: • 355 
S b j c t : 1419 
Query: 296 
S b j c t : 1479 
Query: 236 
S b j c t : 1539 
Query: 176 
S b j c t : 1599 
Query: 116 
S b j c t : 1559 
Figure 24. The best BLAST matches for AAAFJAU. 
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R e s u l t s of Database Search 
D e t a i l s of request AAAFOCG 
Laboratory 
L i b r a r y 
P l a t e 
P o s i t i o n 
Species 
T i s s u e 
D i r e c t i o n 
Sequence. 
HGMP-RC 
CA 
10 
H04 
Human 
L i v e r 
forward 
•CAAGCTGCGNA.A.^TCATCC.ATA.»LCAGCCTTC.=.GTTGCTCTTTTGTTGCCT 
TGGGCCTGTGTTNCTCG.AGCTCAAC.y^GTGCAGTTTGTTTCTNGATTTGN 
CTCTCCTTCTCAGAAAGTGTGCATATATCTGCATGGAiGGTGAATGTTTC 
AGCATTAAACTCTTTGGGA.5iCGTATGTTTCATCG.tiCCTCC.=..3AGCTGAAA 
AGMATGGTCGCCTGTTCACC.SuNGGATTCTGTGCAG.=ATTTGGGTG.2iCTCT 
GTCACTTACTGGCGTTTTCTCATGCA=.CACACATAACTGGTTCAAGGACC 
ACGG.ATAG.WAGTCTTCTTGCACAGGGC.WTCTTTTTGGTTCAGGATGTT 
TACAACATTTGGCTTCGGNCA.AGGGCTCCNA.A.AGGTTATCG.2LTACCNTCG 
ACNCCGAGGGGGGGGCCCGN.ACCCAGTTTTGGGNCCCTAG^rGAGGGGTNA 
NTGGGCCTGGGGNATCAATGGCANANTTGTCCCNGGTN.=u2.rrGGN.\CCCC 
NC.«J.AATCCCANNAV^ICGGCCGGGGG.^T.A.A.AGNTNT.=-.!.CNGGGGGGCCA 
ANNNTNANTANCAATAATGGNTGGGNTCNCTCCCTCNCCGGG.SLCCTNNGN 
C.!iATTATANNTTCGCACCCGGNGGGGNGGGGTTTGMNCCCCTCCCCCA 
Figure 25. Sequence of C10H04, AAAFOCG. 
R e s u l t s of Database Search 
The following best matches are found fo r your requested sequence 
Seqid Database Percent Matching Length D e s c r i p t i o n 
AAAFOCG genbank 95 222 232 human messenger m a f o r serum albumin (hs 
AAAFOCG genbank 95 221 232 sequence 1 from patent us 4914027. 
AAAFOCG genbank 95 221 232 a r t i f i c i a l sequence for human serum albutr. 
AAAFOCG genbank 95 221 232 h.sapiens (pxl53) gene for serum albumin. 
AAAFOCG genbank 95 221 232 h.sapiens (pxl53) gene for serum albumin 
AAAFOCG' genbank 95 221 232 a r t i f i c i a l sequence f o r the pr o t e i n f u s i c 
AAAFOCG genbank 94 219. 232 human serum albumin. 
AAAFOCG genbank 94 219 232 h.sapiens mrna f o r serum albumin. 
AAAFOCG genbank 94 219 232 human serum albumin (alb) mrna, complete 
AAAFOCG genbank 94 219 232 h.sapiens mrna f o r albumin. 
AAAFOCG genbank 90 210 232 macaca mulatta serum albumin mma, 3 end. 
AAAFOCG swi s s p r o t 89 58 75 serum albumin precursor. 
AAAFOCG swi s s p r o t 72 55 76 • serum albumin precursor. 
AAAFOCG swi s s p r o t 72- 54 74 serum albumin precursor. 
AAAFOCG swi s s p r o t 71 54 76 serum albumin precursor. 
AAAFOCG swi s s p r o t 59 53 76 serum albumin precursor. 
AAAFOCG swi s s p r o t 70 52 74 serum albumin precursor (fragment). 
AAAFOCG swi s s p r o t 47 ' 37 78 a l p h a - f e t o p r o t e i n precursor (alpha-fetogl 
AAAFOCG swi s s p r o t 45 36 78 a l p h a - f e t o p r o t e i n precursor (alpha-fetogl 
AAAFOCG swi s s p r o t 35 25 73 serum albumin precursor. 
AAAFOCG swi s s p r o t 39 31 78 a l p h a - f e t o p r o t e i n precursor (alpha-fetogl 
AAAFOCG swi s s p r o t 38 30 73 a l p h a - f e t o p r o t e i n precursor (alpha-fetogl 
AAAFOCG cdna matches to other cDNj^'s i n the database. 
23 e n t r i e s i n the database matched the sea r c h request. 
Figure 26. The listed BLAST matches of AAAFOCG. 
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R e s u l t s of Database S e a r c h 
AAAFOCG genbank 
> HSALBl V00494 Human messenger RNA f o r serum albumin (HSA). 
L e n g t h .= 2055 
Minus S t r a n d HSPs: 
Score = 1070 (295.7 b i t s ) . E x p e c t = 2.8e-80, P = 2.8e-80 
I d e n t i t i e s = 222/232 ( 9 5 * ) , P o s i t i v e s = 222/232 (95S), S t r a n d = Minus 
Query: 242 CCAAATTCTGC.l.CAaAATCCNTGaTGAAC.=.GGCGACCATNCTTTTCAGCTCTGG.AGGTCG 183 
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I t I I I I I 
S b j o t : 1532 CCAAATGCTGCACAG.A.\TCCTTGGTGAACAGGCG.:\CCATGCTTTTCAGCTCTGGAAGTCG 1591 
Query: 182 ATGAAACATACGTTCCCAAAGAGTTTA.ATGCTG.^CATTCACCTTCCATGCAGATATAT 123 
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 11 I I I I I I I I I I I I I I I I I I I I 
• S b j c t : 1592 ATGAA.aLCATACGTTCCCA.A.AGAGTTTAATGCTG.A.A.ACATTCACCTTCCATGCAGATATAT 1651 
Query; 122 GCACACTTTCTGAGA.AGGAGAGNCAAATCNAGAAACA.AACTGCACTTGTTGAGCTCGA3N 63 
I I I I I I I I I I I I I M I I I I I I I I I I I I I I I I I I I I I I I I M I I I I I I I I I I I I I I I 
S b j o t : 1652 GCACACTTTCTGAGAAaaAGAG.5LCAAATCAAGAA.ACA.\.^CTGCACTTGTTGAGCTCGTSA 1711 
Query: 62 AACACAGGCCCAAGGCA.ACAAA.=>G.AGCAACTGA.AGGCTGTTATGGATGATTT 11 
I I I I I I I I I I I I I I I ! I I I i I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
S b j c t : 1712 AACACA.AGCCCA.AGGC.A.:iC.A.A.A.AGAGCAA.CTGA.A.AGCTGTT.ATGGATGATTT 17 63 
Score = 272 (75.2 b i t s ) , E:<pect = 2.8e-30, P o i s s o n P(2) = 2.8e-30 
I d e n t i t i e s = 56/58 ( 9 6 % ) , P o s i t i v e s = 56/53 ( 9 6 % ) , S t r a n d = Minus 
Query; 2 96 CTTGAACCAGTTATGTGTGTTGCATGAGA.AAACGCCAGTAAGTGACAGAGTCACCCAA 239 
I I I I I I I I I I I I I M I I I I I I I I I I I I I I I I I I I I I I I I I I n I I I I I I I I I I I I I 
S b j o t : 1479 CCTGAACC.AGTT.ATGTGTGTTGCATGAGA.AA.ACGCCAGTAAGTGACAGAGTCACCA.AA 1536 
Score = 206 (56.9 b i t s ) , E.'icect = 8.5e-32, P o i s s o n P(3) = 8.5e-32 
I d e n t i t i e s = 42/43 ( 9 7 % ) , P o s i t i v e s = 42/43 ( 9 7 % ) , S t r a n d = Minus 
• Query: 361 CAAATGTTGT.=..AACATCCTG.A.ACCA.A.A.A.^GA.MGCCCTGTGCA 319 
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
S b j c t ; 1416 CA.AATGTTGTA.A.^CATCCTG.=v.AGCAAA.AAGAATGCCCTGTGCA 1453 
> 101999 101999 Sequence 1 from p a t e n t US 4914027. 
Length = 1880 
Minus S t r a n d HSPs: 
Score = 1051 (293.2 b i t s ) , E:-cpect = 1.8e-79, P = 1.8e-79 
I d e n t i t i e s = 221/232 ( 9 5 % ) , P o s i t i v e s - 221/232 ( 9 5 % ) , S t r a n d = Minus 
CCAAATTCTGCACAGAATCCNTGGTGAACAGGCG.".CCATNCTTTTCAGCTCTGGAGGTCG •IS3 
I I I I M I I I I I I I I I I I I I I I M I I I I I I I I I I I I I I I I I I I I I M I I I ( I I I I 11 
I I I I I I I I I I I I M I I I I I I I I I I I M M I I I I I I I I I I I I I I I I I I I I I I I I M I I I I I 
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
AACACAGGCCCAAGGCAACAAA.AGAGCA.ACTGA.AGGCTGTTATGGATGATTT 11 
I I I I I I I I I I I I I I I I I I I I I I I I I M I I I I I I M I I I I I I I I I I I I I I I 
Query: 242 
S b j c t : 1534 
Query; 182 
S b j c t : 1594 
Query; 122 
S b j o t : 1654 
Query: 62 
S b j c t : 1714 
Figure 27. The best BLAST matches for AAAFOCG. 
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R e s u l t s of Database Search 
D e t a i l s of request AAAFIYE 
Laboratory. 
L i b r a r y 
P l a t e 
P o s i t i o n 
Species 
T i s s u e 
D i r e c t i o n 
Sequence 
HGMP-RC 
CA 
8 
BIO 
Human 
L i v e r 
forward 
CGAGCGGCACCAACAGCGGCGCGAGCA.\GA.AGCGCTTTGAAGTC-.iJU!AAG 
TGGAATGCAGTAGCCCTCTGGNCGTGGG.^TATTGTC-GTTGATAACTGTGC 
CATCTGCAGGAACCACATTATGGATCTTTGCATAG.^ATGTCAAC-CTA.!^CC 
AGGCGTCCGCTACTTCAGA.!VG.!VGTGTACTGTCGCATGGGGAGTCTGTAAC 
CATGCTTTTCACTTCCACTGCATCTCTCGCTGGCTC.!LAAACACG.-.CAGGT 
GTGTCCATTGGCAACAGAGAGTGGGAATTCCAAAAGT.2iTGGGCACT.AGGA 
AAAGACTTCTTNCATCAAGCTTTAATTC-TTTTGTT.^iTTCArrr.i.i.TGACT 
TTCCTNCTGTTACCTAATTACAAATTGG.JVTGGG.ACTGTGTTTT 
Figure 28. Sequence of C08B10, AAAHYE. 
R e s u l t s of Database Search 
The f o l l o w i n g best matches are found fo r your requested sequence 
Seqid Database Percent Matching Length D e s c r i p t i o n 
AAAFIYE genbank 98 253 261 t e s t i c a n [humein, t e s t i s , mma, 3484 nt) . 
AAAFIYE genbank 77 183 236 5c01h06-t7 zea mays cdna clone 5c01h06 5 
AAAFIYE s w i s s p r o t 47 10 21 hy p o t h e t i c a l 13.8 kd protein zk637.l4 i n 
AAAFIYE s w i s s p r o t 34 15 46 g o l i a t h p r o t e i n (gl p r o t e i n ) . 
AAAFIYE s w i s s p r o t 59 13 22 t r a n s - a c t i n g t r a n s c r i p t i o n a l p r o t e i n icpO 
AAAFIYE s w i s s p r o t 59 13 22 t r a n s - a c t i n g t r a n s c r i p t i o n a l p r o t e i n icpO 
AAAFIYE s w i s s p r o t 50 11 22 t r a n s - a c t i n g t r a n s c r i p t i o n a l p r o t e i n icpO 
AAAFIYE s w i s s p r o t 40 9 22 hypot h e t i c a l 37.9 kd protein precursor i n 
AAAFIYE s w i s s p r o t 50 11 22 t r a n s - a c t i n g t r a n s c r i p t i o n a l p r o t e i n icpO 
AAAFIYE s w i s s p r o t 27 5 22 beta-galactosidase (ec 3.2.1.23) ( l a c t a s e 
AAAFIYE s w i s s p r o t 53 7 12 60s ribosomal protein 19. 
AAAFIYE cdna matches to other cDNW s i n the database. 
12 e n t r i e s i n the database matched the search request. 
Figure 29. The listed BLAST matches of AAAFIYE. 
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R e s u l t s of Database Search 
AAAFIYE genbanl< 
> S52147 S62147 t e s t i c a n [human, t e s t i s , mRNA, 3484 n t l . 
Length =3484 
Minus Strand HSPs: 
Score = 1278 (353.1 b i t s ) , Expect = 6.2e-99, P = 6.2e-99 
I d e n t i t i e s = 258/251 (98%), P o s i t i v e s = 258/251 (93%), Strand = Mi.nus 
I I I I I I I I I I I I I I I I I I I M I I I I I I I I I I I I I M I I I I I I I I I I I I I I I I I I I I I I I I 
CCAATGGACACACCTGTCGTGTTTTGAGCCAGCGAGAG.ATGCAGTGGAAGTGAAA.AGCAT 
GGTTACAGACTCCCCATGCGACAGTACACTCTTCTGAAGTAGCGGACGCCTGGTTAGCTT 
l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l 
GGTTACAGACTCCCCATGCGACAGTACACTCTTCTGAAGT.AGCGGACGCCTGGTT.a.GCTT 
GACATTCTATGCAAAGATCCATAATGTGGTTCCTGCAGATGGCACAGTTATCAACCACAA 
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I M I I M I I I I I I 
GACATTCTATGCAAAGATCCATAATGTGGTTCCTGCAGATGGCACAGTTATCAACCACAA 
TATCCCACGNCCAGAGGGCTACTGCATTCCACTTTTTCACTTCAAAGCGCTTCTTGCTCG 
l l l l l l l I I I I I I I I M I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I II 
TATCCCAGGCCCAGAGGGCTACTGCATTCCACTTTTTCACTTCA.AAGCGCTTCTTGCCCG 
CGCCGCTGTTGGTGCCGCTCG 1 
l l l l l l l l l l l l l l l l l l l l l 
> T18274 T18274 5c01h05-t7 Zea mays cDNA clone 5c01h05 5' end. 
Length = 450 
Plus Strand HSPs: 
Score = 703 (194.3 b i t s ) . Expect = l.Oe-50, P = l.Oe-50 
I d e n t i t i e s = 133/235 (77%) , P o s i t i v e s = 183/236 (77%), Strand = Plus 
I I I l l l l l l l l II I II I I M I I I I II II II l l l l l l I I I I I M I I I I 
CAACAAGCGCTTCGAGATCAAGAAGTGGAACGCCGTCGCGCTCTGGGCATGGGATATCGT 
GGTTGATAACTGTGCCATCTGCAGGAACCACATTATGGATCTTTGCATAGAATGTCAAGC 
II II m i l I I I M i n i I II I M i l l l l l l l l l l M i l l II II II II CGTCGACAACTGCGCCATCTGCCGCAACCACATCATGGATCTATGCATCGAGTGCCAGGC 
TAACCAGGCGTCCGCTACTTCAGAAGAGTGTACTGTCGCATGGGGAGTCTGTAACCATGC 
M i l l M I I I II II M i l l Ml II Ml M M I I I I I M I MM I 
GAACCAAGCTAGCGCGACCAGCGAGGAGTGCACTGTCGCTTNGGGTGTCTGTAATCATGC 
TTTTCACTTCCACTGCATCTCTCGCTGGCTCAAAACACG.ACAGGTGTGTCCATTGG 2 51 
M I I M M I I I I I I M I I I I M i l l II II II II M i l l M i l l I 
Query: 251 
S b j c t : 14 
Query: 201 
S b j c t : 74 
Query: 141 
S b j c t : 134 
Query: 81 
S b j c t : 194 
Query: 21 
S b j c t : 254 
Query: 26 
S b j c t : 198 
Query: 86 
S b j c t : 258 
Query: 146 
S b j c t : 313 
Query: 205 
S b j c t : 378 
Figure 30. The best BLAST matches for AAAFIYE. 
From the 1552 sequences consensus sequences were produced from ESTs sequenced 
from both ends. These 1167 consensus sequences (screened rigorously for unwanted 
sequences including vector and alu repeats) were then further analysed in their specific 
semi-ordered adaptor and primer selective "subsets" with ICATOOLS which looks for 
family type similarities. Sequences were grouped into classes (with a parent sequence) 
showing similarity; these sequences matched the same sequences in the database as 
would be expected. 
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Subset CA CB C C CD C E M TOXAL 
Adaptor XT AA XT XX AA XX XX or AA 
Primer 1 C C G G G c C o r G 
Primer 2 C C C A C c Aor C 
Plates C l - C17- C21- C23- C25- M l - C1-C26 
C16 C20 C22 C24 C26 M4 M1-M4 
Number of sequences 529 221 75 79 71 192 1167 
Number of different sequence 209 145 53 49 52 120 636 
classes 
% different sequence classes 40 66 71 62 73 67 54 
Number of unique sequences 159 124 46 38 43 103 513 
% unique sequences 30 56 61 48 61 54 44 
Number of unknown cDNAs 88 18 7 9 3 27 152 
% unknown cDNAs 17 8 9 11 4 14 13 
Number of unique unlcnown 54 14 5 6 2 15 96 
new sequences 
% unique unknown new 10 6 7 8 3 8 8 
sequences 
Number of mitochondrion/ 5 1 10 7 3 1 27 
mitochondria sequences 
% mitochondrion/ 0.9 0.5 13.3 8.9 4.2 0.5 2.3 
mitochondria sequences 
Table 3. Composition of fetal tissue cDNA fragment subset sequences. 
Unique sequences were of no similarity to any others sequenced in this study. Sequence classes were 
defined by similarity between famihes by ICATOOLS. Unknowns showed no match to a cDNA of 
known purpose, whilst unique unknowns showed no match at all. 
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Subset CA 
Adaptor: I T 
Primer 1: C 
Primer 2: C 
Number of sequences: 529 
Parent Family Number % Description 
CA-10-H04 205 113 21.4 Human messenger RNA for serum albumin (1532-1763) 
CA-10-F05 188 29 5.5 Human mRNA for alph i-l-microglobuUn (245-575) 
CA-10-B04 202 23 4.3 Human coagulation factor V mRNA, complete cds 
CA-10-H02 204 12 2.3 Human mRNA for ankyrin (variant 2.1) 
CA-11-H03 153 11 2.1 A. officinalis mRNA for asparagine 
CA-10-D02 199 9 1.7 Human 90-kDa heat-shock protein gene (1977-2245) 
CA-13-C11 169 9 1.7 Mouse mRNA for protein C, complete cds 
CA-10-E03 120 9 1.7 Testican [human, testis, mRNA, 3484 nt] 
CA-10-H09 158 8 1.5 Rat mRNA for ribosomal protein S5 
CA-11-H04 146 8 1.5 H. sapiens partial cDNA sequence; clone 96A07 
CA-11-C02 135 8 1.5 IB2318 H. sapiens cDNA 3' end similar to EST06268 
Sequence Database % Matching Length ID and Brief Description 
CA-10-H04 genbank 95 222 232 V00494 serum albumin 
CA-10-F05 genbank 90 301 331 X04494 alpha-1-microglobuUn 
CA-10-B04 genbank 98 191 193 Ml6967 coagulation factor V 
CA-10-H02 genbank 95 62 65 XI6609 ankyrin (variant 2.1) 
CA-11-H03 genbank 67 42 62 X67958 asparagine 
CA-10-D02 genbank 98 264 269 Ml6660 heat-shock protein) 
CA-13-C11 genbank 77 38 49 D10445 protein C 
CA-10-E03 genbank 99 238 240 S62147 testican 
CA-10-H09 genbank 86 227 262 X58465 ribosomal protein S5 
CA-11-H04 genbank 92 197 214 Z25122 partial cDNA 96A07 
CA-11-C02 genbank 97 117 120 T15970 CDNAEST06268 
Table 4. Composition of fetal tissue cDNA fragments in subset CA. 
The eleven most frequent sequence classes, and percent best match results of a database search for these 
are listed. Base co-ordinates defining GenBank entries, which characterise cDNA sequence classes, are 
given in parenthesis to distinguish between different fragments of a given transcript. 
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Subset CB 
Adaptor: AA 
Primer 1: C 
Primer 2: C 
Number of sequences: 221 
Parent Family Number % Description 
CB-18-C03 97 25 11.3 Seq2269 Homo sapiens cDNA clone b4HFLSK 
CB-17-F03 130 11 5.0 Human mRNA for aldolase B 
CB-17-B11 101 10 4.5 Sequence 1 from patent US 4839283 
CB-17-A06 142 5 2.3 Human mRNA for hepatic triglyceride lipase (HTGL) 
CB-17-G08 116 5 2.3 mRNA for translationally controlled tumour protein 
CB-18-D10 7 4 1.8 Human mRNA for 1-alpha-1-antitrypsin 
CB-17-H10 121 4 1.8 Human mRNA for S-protein 
CB-17-B09 111 4 1.8 H. sapiens NAP (nucleosome assembly protein) 
CB-17-D08 91 3 1.4 EST06257 Homo sapiens cDNA clone HIBBD2 5' end 
CB-18-A08 53 3 1.4 Human transaldolase mRNA 
Sequence Database % Matching Length ID and Brief Description 
CB-18-C03 genbank 96 128 132 T24081 cDNA clone b4HFLSK 
CB-17-F03 genbank 98 202 205 X02747 aldolase B 
CB-17-B11 genbank 98 302 306 101352 US patent 4839283 
CB-17-A06 genbank 93 293 313 X07228 HTGL 
CB-17-G08 genbank 99 347 348 XI6064 tumour protein 
CB-18-D10 genbank 99 262 263 A01846 1-alpha-1-antitrypsin 
CB-17-H10 genbank 90 220 243 X03168 mRNA for S-protein 
CB-17-B09 genbank 91 216 236 M86667 H. sapiens NAP 
CB-17-D08 genbank 97 38 39 T08366 cDNA clone HIBBD2 
CB-18-A08 genbank 95 112 117 L I 9437 human transaldolase 
Table 5. Composition of fetal tissue cDNA fragments in subset CB. 
The ten most frequent sequence classes, and percent best match results of a database search for these are 
listed. Base co-ordinates defining GenBank entries, which characterise cDNA sequence classes, are 
given in parenthesis to distinguish between different fragments of a given transcript. 
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Subset C C 
Adaptor: TT 
Primer 1: G 
Primer 2: C 
Number of sequences: 75 
Parent Family Number % Description 
CC-21-G08 17 10 13.3 Human messenger RNA for serum albumin (1424-1734) 
CC-21-H05 53 5 6.7 Human mitochondrion, complete genome (6382-6827) 
CC-21-F02 51 5 6.7 Human mRNA for alpha-l-microglobulin (419-762) 
CC-21-D09 10 3 4.0 EST276 Homo sapiens cDNA clone lOGl 1 
CC-21-B03 48 2 2.7 Human ribosomal protein L12 mRNA complete cds 
CC-21-F03 43 2 2.7 Human HL60 3' directed Mbo I cDNA HUMGS01951 
CC-21-C03 35 2 2.7 Human HL60 3' directed Mbo I cDNA HUMGS01373 
Sequence Database % Matching Length ID and Brief Description 
CC-21-G08 genbank 92 288 311 V00494 serum albumin 
CC-21-H05 genbank 94 217 230 J01415 mitochondrion 
CC-21-F02 genbank 98 338 344 X04494 alpha-1-microglobuHn 
CC-21-D09 genbank 97 102 105 T24701 cDNA clone lOGll 
CC-21-B03 genbank 96 212 219 L06505 ribosomal protein L12 
CC-21-F03 genbank 83 51 61 D20969 HL60 3' cDNA clone 
CC-21-C03 genbank 79 51 64 D20399 HL60 3' cDNA clone 
Table 6. Composition of fetal tissue cDNA fragments in subset CC. 
The seven most frequent sequence classes, and percent best match results of a database search for these 
are listed. Base co-ordinates defining GenBank entries, which characterise cDNA sequence classes, are 
given in parenthesis to distinguish between different fragments of a given transcript. 
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Subset CD 
Adaptor: I T 
Primer 1: G 
Primer 2: A 
Number of sequences: 79 
Parent Family Number % Description 
CD-23-F02 17 10 12.7 H. sapiens (pXL53) for serum albumin (1409-1773) 
CD-23-F05 45 8 10.1 Human mRNA for alpha-1-microglobulin (245-647) 
CD-23-D02 40 7 8.9 Human mitochondrion, complete genome (7028-7246) 
CD-23-B08 49 2 2.5 
CD-23-A05 37 2 2.5 Human mRNA for alpha 1-antitrypsin (899-1316) 
CD-23-F01 35 2 2.5 H. sapiens partial cDNA sequence clone HECD09 
CD-23-D01 28 2 2.5 Human HepG2 3' directed Mbo I cDNA clone hmOldOS 
CD-23-C06 27 2 2.5 EST276 Homo sapiens cDNA clone lOGl 1 
CD-23-B05 26 2 2.5 Human insulinoma rig-analogue mRNA encoding DBP 
CD-23-E12 2 2 2.5 Human protein icinase mRNA (1472-1734) 
CD-23-G05 13 2 2.5 Human H3.3 histone class C mRNA complete cds 
Sequence Database % Matching Length ID and Brief Description 
CD-23-F02 genbank 97 356 365 A03758 serum albumin 
CD-23-F05 genbank 96 387 403 X04494 alpha-1-microglobulin 
CD-23-D02 genbank 99 218 219 JO 1415 mitochondrion 
CD-23-B08 genbank 
CD-23-A05 genbank 96 403 418 X01683 alpha 1-antitrypsin 
CD-23-F01 genbank 92 165 178 Z17841 partial cDNA sequence 
CD-23-D01 genbank 97 131 135 D11765HepG2cDNA 
CD-23-C06 genbank 97 102 105 T24701 cDNA clone lOGll 
CD-23-B05 genbank 95 313 327 J02984 insulinoma rig-analogue 
CD-23-E12 genbank 97 256 263 M59287 protein kinase mRNA 
CD-23-G05 genbank 97 334 343 Ml 1353 H3.3 histone class C 
Table 7. Composition of fetal tissue cDNA fragments in subset CD. 
The eleven most frequent sequence classes, and percent best match results of a database search for these 
are listed. Base co-ordinates defining GenBank entries, which characterise cDNA sequence classes, are 
given in parenthesis to distinguish between different fragments of a given transcript. 
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Subset C E 
Adaptor: AA 
Primer 1: G 
Primer 2: C 
Number of sequences: 71 
Parent Family Number % Description 
CE-25-E11 35 12 16.9 Human mRNA encoding alpha-fetoprotein 
CE-25-A03 44 2 2.8 Human glycine-gamma-globin, 3' end (272-536) 
CE-25-D03 43 2 2.8 EST346 Homo sapiens cDNA clone 12H7 
CE-25-E03 41 2 2.8 Human mRNA for transferrin receptor 
CE-25-H10 37 2 2.8 Human mRNA for asialoglycoprotein receptor (597-837) 
CE-25-E09 30 2 2.8 Human mitochondrion, complete genome (15360-15632) 
CE-25-C08 3 2 2.8 EST01423 Homo sapiens cDNA clone HRBBA08 
CE-25-G02 13 2 2.8 Human humFib mRNA for fibrillarin 
CE-25-E05 11 2 2.8 Human messenger RNA for alpha-globin (189-553) 
Sequence Database % Matching Length ID and Brief Description 
CE-25-E11 genbank 99 227 228 V01514 alpha-fetoprotein 
CE-25-A03 genbank 90 241 265 M15386 glycine-gamma-globin 
CE-25-D03 genbank 94 121 128 T24771 cDNA clone 12H7 
CE-25-E03 genbank 97 81 83 X01060 transferrin receptor 
CE-25-H10 genbank 99 239 241 X55284 asialoglycoprotein 
CE-25-E09 genbank 97 266 273 J01415 mitochondrion 
CE-25-C08 genbank 98 276 279 M79268 cDNA HRBBA08 
CE-25-G02 genbank 96 170 176 X56597 fibrillarin 
CE-25-E05 genbank 96 353 365 V00493 alpha-globin 
Table 8. Composition of fetal tissue cDNA fragments in subset CE. 
The nine most frequent sequence classes, and percent best match results of a database search for these 
are listed. Base co-ordinates defining GenBank entries, which characterise cDNA sequence classes, are 
given in parenthesis to distinguish between different fragments of a given transcript. 
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Subset M 
Adaptor: TT 
Primer 1: C 
Primer 2: C 
Number of sequences: 192 
Parent Family Number % Description 
M-03-E06 126 24 12.5 H. sapiens (pXL53) gene for serum albumin (1548-1773) 
M-02-E12 110 7 3.6 Bovine rotavirus outer capsid protein (VP4) mRNA 
M-03-G12 95 4 2.1 Human 90-kDa heat-shock protein gene (1985-2245) 
M-02-C11 121 4 2.1 IB3518 H. sapiens cDNA 3' end similar to EST04951 
M-03-D11 109 4 2.1 H. sapiens putatively transcribed partial cDNA Z21370 
M-03-A05 96 3 1.6 Human RNA polymerase subunit hRPB 33, mRNA 
M-02-H02 82 3 1.6 Testican [human, testis, mRNA, 3484 nt] 
M-02-B08 45 3 1.6 Seq2269 Homo sapiens cDNA clone b4HFLSK 
M-02-D06 125 3 1.6 Human phospholipase C-gamma mRNA, complete cds 
M-02-F05 123 3 1.6 Human mRNA for alphs I-1-microglobulin (245-694) 
M-02-G08 117 3 1.6 H. sapiens partial cDNA sequence; clone 96A07 
Sequence Database % Matching Length ID and Brief Description 
M-03-E06 genbank 96 219 226 A03758 serum albumin 
M-02-E12 genbank 72 35 48 M92986 outer capsid protein 
M-03-G12 genbank 96 251 261 Ml6660 heat-shock protein 
M-02-C11 genbank 94 287 304 T16120ffi3518cDNA 
M-03-D11 genbank 94 149 158 Z21370 partial cDNA 
M-03-A05 genbank 87 249 283 J05448 RNA polymerase 
M-02-H02 genbank 97 191 195 S62147 testican 
M-02-B08 genbank 95 239 251 T24081 cDNA clone b4HFLSK 
M-02-D06 genbank 66 47 71 M34667 phosphohpase 
M-02-F05 genbank 97 375 384 X04495 alpha-1-microglobulin 
M-02-G08 genbank 91 62 68 Z25122 partial cDNA 
Table 9. Composition of fetal tissue cDNA fragments in subset M . 
The eleven most frequent sequence classes, and percent best match results of a database search for these 
are listed. Base co-ordinates defining GenBank entries, which characterise cDNA sequence classes, are 
given in parenthesis to distinguish between different fragments of a given transcript. 
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After the rigorous BLAST and ICATOOLS sequence analysis 636 (54%) different 
sequence classes were identified; 513 (44%) of these ESTs were only seen once. 
Various percentages of different sequence classes were generated for each of the subsets, 
averaging about 67% except for CA with only 40%. The same pattern was seen with the 
percentages of unique sequences, averaging 56% except for 30% of the ESTs being 
unique in the CA subset. The mixed tissue subset data was not significantly different to 
that generated by the liver tissue subsets. 
The biological purpose of 152 (13%) of the ESTs generated in this study was unknown, 
whilst 96 (8%) of the sequences were totally new: unique to the public databases and still 
of unknown function representing yet to be determined genes. Significant differences in 
the proportions of unknowns were seen across the different subsets. 
Only a very small amount of mitochondrion sequences (27, 2.3%) were produced. These 
were again unevenly distributed in the different subsets suggesting selection for these 
cDNAs being exhibited in some cases giving a figure inproportionately high for the 
amount of mitochondrial species present. No ESTs generated showed similarity matches 
with database intron sequences, showing successful removal of DNA 
Within each subset no antisense sequences were identified, suggesting positive semi-
ordering of the cDNA fragments was achieved. The profiles of the compositions of each 
of the subsets was also very significantly different as seen in the previous six tables. 
Indeed the populations sequenced from each subset were quite different; ICATOOLS 
was used to show this by analysis of some subsets combined together as well as 
separately. 
Subsets CA &CB C A & C C C A & C D 
Adaptor T T & A A T T & T T XT & T T 
Primer 1 C & C C & G C & G 
Primer 2 C & C C & C C & A 
Number of different sequence classes 209 & 145 209 & 53 209 & 49 
Total number of different sequence classes 354 262 258 
Combined number of different sequence classes 328 249 253 
% overlap between sequence classes 7.3 5.0 1.9 
Table 10. Overlap between cDNA fragment subset sequences. 
Unique sequences were of no similarity to any others sequenced in this study. Sequence classes were 
defined by similarity between families by ICATOOLS. 
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The specificity of the cDNA fragment sorting was effective as the amount of overlap of 
sequence classes between pairs of subsets was shown to be only 5% on average. 
Different parts of the sequences such as those for serum albumin, alpha-fetaprotein, and 
alpha-1-microglobulin were seen in a number of sequences in different subsets; other 
sequence families were perhaps also biased towards and identified more than once. In 
general many different ESTs were generated of much biological value. 
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4. DISCUSSION 
4.1. Methods utilised and results obtained 
Whilst the fastidious extraction of high quality RNA by two fractionations, and other 
purification stages is a lengthy process, it is imperative to the production of a good 
cDNA library. The oligo (dT)25 beads method of mRNA purification from total RNA 
produces a very pure product, using many washes before the final elution to wash off and 
dilute any possible contaminants. Other quicker methods and similar bead methods exist 
to produce mRNA direct from tissue, and are successful but obviously prone to 
contamination with other types of RNA and DNA. 
As PCR is used subsequently any small amounts of unwanted products would be 
magnified to observable levels, and so the inclusion of traditional based methods 
involving centrifugation is expedient. Considering the amount of time spent utilising the 
library, all expenditure in adding value to it by quality production procedures is energy 
well directed. 
The method used was shown to be worthwhile and successful as only small numbers of 
mitochondrial sequences were generated, and these might have been selected for in some 
of the subsets. This is a significant achievement as any mitochondrial contamination 
present would have high levels of expression; the redundancy of sequencing is also 
reduced significantly by its absence. The fact that no intron matching ESTs were seen 
was good, but even more indisputable evidence that no genomic DNA derived cDNA 
was present could be shown. Firstly the control would be a PCR using the cDNA as 
template between two facing primers on a known regular house keeping gene within the 
gene exon, before moving both primer sites down a number of bases until one is within 
an identified intron for another PCR. No exponentially generated product would be 
expected to be seen in the second instcince if no intron DNA was present. Other EST 
projects have sometimes generated known intron sequences. 
The production of a ready to use, quality controlled vector on a large scale was of great 
importance. Previous methods involved ligating four different adaptors on to a relatively 
small amount of double digested vector to create the necessary overhangs for subsequent 
ligation with the prepared cDNAs fragments. This obviously introduced the inherent 
risks involved at a late stage, including no guarantee of 100% successful ligation or 
79 
removal of unsuccessful substandard vector. The new vector is easily produced in large 
quantities, with a simple cut and column purification. The use of this new vector 
reduced the occurrence of no cDNA insert in white clones; this reduced wastage and 
increased efficiency. 
In this study ssDNA templates were generated from the cDNA clones because in general 
they produce better quality and longer ESTs. Plasmid preparation methods were stiU 
very labour intensive often involving centrifugation, were not 96 format compatible and 
therefore of low throughput. The template purification methods used were 96 format 
compatible, and automation could often be used to reduce manpower required. Perkin-
Elmer 9600 thermal cyclers were used for the PCRs in a 96 format, and then the 
Beckman Biomek automated workstation could be used for the capture of the PCR 
products and washing steps. 
In contrast with other large studies, helper phage was used with pBluescript to grow 
ssDNA for purification to generate ESTs. This meant the cDNAs could be kept in a 
good storage plasmid vector whilst being able to produce ssDNA with out recloning. 
The innovative growth of the DNA within the filtration plates and subsequent filtration 
reduced the transference steps and the need for inefficient awkward centrifugation. A 
Tecan Robotic Sample Processor with disposable tip option available at the Resource 
Centre was used for some transference steps. Robotic steps are often slow but do not 
involve user real time, so ultimately increase throughput and reproducibility. Much 
titration of relative amounts of helper and beads required was needed to optimise the 
protocols to a robust procedure. Customised lacZ beads could be made, but not to such 
a guaranteed quality, that gives a reliable sequence template. 
As the templates were ssDNA and of good general quality, Taq terminator cycle 
sequencing with dye labelled primer in a one tube reaction could be used. Removal of 
excess terminators was not a trivial task, but was decided the preferred option rather 
than four separate reactions requiring pooling and ethanol precipitation required for 
primer cycle sequencing. KS dye labelled primer kits were not commercially available 
either, whereas this preferred customised primer could be used with the available dye 
labelled terminator kits. The length of read and even signal may have been compromised 
by the use of terminator cycle sequencing, but this chemistry completely eliminates 
labelled false stops. Sequenase T7 sequencing could have been utilised for increased 
accuracy of base calling and longer read length, but a much greater amount of ssDNA 
template would have been required and costs would have increased. The Apphed 
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Biosystems four dye per lane technology was mainly used to achieve a greater 
throughput. Up to two ABI 373A DNA sequencers were available for real time data 
collection, and were used for full scans (24 or 36 samples) and the quicker basesprinter 
(18 samples) runs. 
Various excess terminator removal methods were evaluated: both phenol/chloroform 
extractions and spin column purification were both found to be successful, the preferred 
option dependent on the user and daily throughput. Columns were found more suitable 
once the apparatus for large numbers was set up, specifications for column type was 
known and large numbers were routinely required. Using columns reduced the user 
variability found using phenol/chloroform and ethanol precipitations, provided that the 
exact successful specifications for the use of columns was strictly adhered to. 
Purification columns were used 96 (24x4 with the appropriate bench top centrifuge 
inserts) at a time for efficiency. The quality of the ssDNA could be checked prior to the 
sequencing reaction to reduce wastage, some cDNAs would not produce suitable 
templates. The PCR based method complemented the lacZ method which could only 
generate the one strand suitable for sequencing. The rate limiting step varied mainly 
from template production, the excess terminator removal or the running of samples on 
the automatic sequencers. 
As the public sequence databases get bigger and contain more sequences (GenBank April 
1995 release contained 352 414 sequences and 286 094 556 bases, about 20% human), it 
obviously becomes much harder to generate new sequences of unknown biological 
purpose. 
The restriction fragment sorting yielded distinct semi-ordered subpopulations of the 
cDNA fragments, produced by cutting the cDNA with a type IIS restriction 
endonuclease, Fok I . The fidelity of the T4 DNA ligase catalysed reaction is the basis for 
the sorting of the cDNA fragments into distinct subsets by two base specific adaptoring. 
Specific primer annealing and extension are the prerequisites for the partitioning of the 
cDNA fragments by PCR employing two single base specific primers. 
The definition of a different sequence was rigorous in this study as ICATOOLS was 
additionally used to give families of sequence classes, but on average 54% of all ESTs 
generated were of a different class. A total percentage of 44% were generated once 
only. The variation across the subsets might be due to the final numbers in each; it may 
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be that as more of each subset are sequenced, the chance of sequencing the same species 
is greater, explaining the lower figures for subset CA. Data needs be analysed in real 
time with regard to sequencing, so numbers against different classes could be plotted for 
each subset to be in direct comparison to confirm this. A more complex population 
would produce redundant ESTs at a later stage, this might be the case for subset M: the 
complexity of a given subset may be further enlarged by increasing the heterogeneity of 
the source material from which the RNA was isolated. From the data it is suggested that 
sequencing no more than 500 sequences from each subset would be optimal for the 
greatest efficiency in finding different sequence classes in over 50% of ESTs, with a high 
proportion of unique sequences. Indeed the rationale for the restriction fragment sorting 
technology is that combining distinct cDNA subpopulations, of relatively low 
complexity, ensures a greater representation of transcribed sequences than that achieved 
by conventional libraries. Subtraction methods or pre-screening methods would be 
required for conventional libraries to avoid redundancy increasing significantly as 
numbers of ESTs generated from the library increases. 
If small numbers (hundreds) of different subsets are continually sequenced no great 
increase in the present low rate of redundancy of output should be encountered, as 
different populations are proven to have overlap of only about 5% (1.9, 5.0 and 7.3 for 
those studied). Many different subsets involving different selective adaptors, primers, 
and different tissues can easily be generated for sequencing purposes. The small amount 
of overlap between subsets is attributable to mishgation, and the extension of PCR 
primers with a 3' end mismatch. The amplification of adaptored fragments may 
exaggerate the otherwise undetectable effects of misligation. The incorporation of PCR 
into the sorting procedure provides a means of enriching the proportion of low 
abundance transcripts: the proportions of unknown sequences and mitochondrial 
sequences may reflect this effect. 
In total 13% of the ESTs generated represented potentially 152 unidentified genes, and 
8%, 96 new gene sequences. This is a relatively high return for the amount of 
sequencing, which still shows the overall value of ESTs at this stage in the HOP 
compared to the slower genome sequencing. More interesting and biologically 
significant sequences of greater use to mapping strategies are efficiently realised, which is 
important until the required technologies are in place to sequence much faster and 
cheaper. 
82 
Variation of unknown cDNAs seen in each of the subpopulations is explained by the 
distribution of selecting bases created by the Fok I cuts. The differences in the numbers 
of mitochondrial sequences in each subset can be explained by this specific selection for 
them in certain fragment populations. This also explains the high numbers of some 
species in some subsets too, which is not a true reflection of expression levels. For 
example 21% of the sequences in CA shows similarities to serum albumin which is 
produced in fetal liver, but is not evident in subset CE where alpha-fetoprotein sequences 
were predominant (17%). Proof of the correct base selection and hypothesis for positive 
subdivision could be further proven by searching for the Fok I restriction sites in the 
exon sites, looking at the four base overhang produced and seeing whether this is as 
would be expected to have been selected for by the respective primers and adaptors. 
The sorting technology including base specific ligation may have many other applications 
in molecular biology including fragment profiling and sequencing. 
Successful data management for collection, early analysis, editing, database searching 
and analysis is required for a productive EST program. Such large amounts of data are 
produced, that efficient and proficient use of it must be made to optimise its biological 
value. This was achieved quite successfully, with some parts evolving as required and 
deemed appropriate. Complete integration of the system so the informatics worked on a 
biological level to produce exactly what was required, whilst being able to adapt to 
future possible so far unidentified needs was necessary. Much forethought, planning and 
collaboration was obviously prudent in this area. The cDNA database is accessible to all 
Resource Centre users and will soon be available on the world wide web (www) via the 
HGMP RC information services. The provision of this data and the biological resources 
in the form of cDNA clones or PCR products on high density nylon membranes is 
important for future advances to be made in adding biological value such as mapping 
information or tissue localisation to the ESTs. 
Good quality RNA was fastidiously made to make the semi-ordered restriction fragment 
sorted cDNA hbrary. An improved vector was used to produce the cDNA clones, from 
which many quality ssDNA templates were routinely made for automatic sequencing 
using further developed methods. Much good quality EST data was successfully 
generated from semi-ordered populations using these protocols and the latest 
technologies. Detailed analysis revealed the great value of the innovative Ubrary 
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production and template technologies, and the overall strategy. Indeed combining data 
from such semi-ordered populations and different tissues increases the complexity of a 
cDNA library immensely and hence minimises the redundancy encountered in systematic 
sequencing programmes, which was the objective. Ultimately this provides a faster route 
to identification of new transcribed sequences, and genes to significantly forward the 
Human Genome Project. 
4.2. Further experiments and future developments 
A concerted effort towards a public-domain human gene map and amassing information 
on human genes is now being made by many scientific institutions and private companies 
working together (Genome Digest, 1995). Shared materials and co-ordination of 
activities minimise overlap; and the information gained will be put into public databases. 
Various consortia are exchanging information whilst pursuing different but 
complementary strategies. cDNA libraries and the short identifying partial sequences of 
cDNAs, ESTs, are the starting material for many of the strategies: mapping them back to 
their origin in the genome by hybridisation or PCR approaches. By ampUfying the 
corresponding sequence from genomic DNA using suitably designed primers to the EST, 
it is converted to a "sequence tagged site" (STS) which,can be mapped to a location on 
the genome. The EST database (dbEST) at the US National Center for Biotechnology 
Information (NCBI) contains over 8500 although the number of unique genes 
represented is much smaller than this as more than one EST can be derived from a single 
gene. The mapping of ESTs has only recently begun in earnest but over 1100 have been 
mapped so far. This is seen as the best way forward to rapid assembly of a partial 
transcription map of the genome; to complement the HGP sequencing of the whole 
human genome. 
The Merck Expressed Gene Initiative is aiming to isolate one cDNA clone for each 
expressed human gene, firstly obtaining ESTs frorn over 200 000 clones. Highly 
expressed genes are likely to be over represented, so techniques such as oligonucleotide 
fingerprinting and subtractive hybridisation procedures will be used to identify clones 
representing more rare expressed genes. A set of unique genes (the Merck Gene Index), 
using the longest cDNAs will then be built. 
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The IMAGE consortium is using shared arrayed cDNA libraries for gene sequencing, 
mapping and expression studies, to gain the maximum amount of information from the 
same resource. One pass sequencing of the 3' ends generated nearly 28 000 usable 
sequences, with many not identical or similar to known genes. About 10 000 of the new 
human gene transcripts were registered with the European Bioinformatics Institute 
(EBI), and over 3000 of these had been assigned to chromosomes by somatic cell 
hybridisation. All information on these transcripts has been registered with the Genome 
Data Base (GDB): IMAGE is also providing the cDNA clones for the Merck Initiative. 
The international EST consortium co-ordinated by the Sanger Centre, includes 
laboratories from around the world, and is working in concert with IMAGE. The goal is 
to complete a comprehensive framework map of the human genome including the 
majority of genes, integrated with genetic markers such as microsatellite repeats within 
the next couple of years. The map should be much denser than current genetic maps 
with a resolution of 0.5 Mb. The strategy is to map genes by using tag sequences from 
the 3' ends of cDNAs (ESTs) and from CpG islands (genomic regions that signal the 
presence of a gene). These gene tag sequences are used to develop STSs which are 
mapped by PCR with radiation hybrid panels or against YACs. 
Integration of the information emerging from the different mapping approaches is vital in 
order to build up a complete gene map. The same STSs will be mapped onto the CEPH 
mega-YACs and the Caltech bacterial artificial chromosome (BAC) clones as well as the 
radiation hybrids. As progress is made on the gene map it will provide reagents and 
much information that can be applied towards the eventual goal of sequencing the 
genome. Indeed the sequence level map of the entire human genome with 99% coverage 
and 99.99% accuracy in the coding regions is still estimated to be complete within the 
next 5-10 years. The information generated by the public domain gene mapping projects 
is accessible from the dbEST at the NCBI, which is mirrored at the EBI. Further 
development of databases to keep up with all the data produced and possible other 
information like expression data is necessary. Support in funding for these projects is 
still forthcoming from many sources including the NIH National Center for Human 
Genome Research, the UK Medical Research Council (MRC), the US DOE and the 
Wellcome Trust. The European Commissions new Biomedicine and Health Research 
Programme (Biomed 2) is also injecting money towards transnational genome research 
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projects. Rapid developments are presentiy being made in the human gene map initiative, 
with much hard data being produced with these strategies. 
The many ESTs generated are simultaneously being used for many other purposes, 
including the determination of fiil l length cDNA and genomic sequences of the mapped 
genes. These can be used to obtain expression of the proteins, to determine their normal 
biological functions, accelerate disease gene associations, and their RNA and protein 
products. The gene or gene fragments may then be used for many other developments 
including mapping, tissue typing, individual or forensic identification, and locating gene 
regions associated with genetic disease. Sequence information culminates in the 
complete genetic sequence but other advances in biological discovery such as 
understanding of function and the use of the genes in diagnosis and treatment of disease 
requires further imagination. 
There have been many recent developments in sequencing technologies and automation 
(robotics) that enable the faster generation of greater numbers of better ESTs more 
economically. This will lead to rapid completion of sequencing unknown cDNAs and the 
eventual sequencing of the whole human genome: indeed the emphasis is already turning 
from mapping to large scale sequencing (Science, 1995). Some specific advances have 
been made with regard to high throughput ds DNA and ss DNA template preparation 
methods, including 96 format plasmid preparations (i.e. Qiagen). Complete automation 
using robots such as the Amersham Vistra and Perkin-Elmer Turbo Catalyst are 
perceived to generate a large number of quality templates. Sequencing chemistries have 
continually been improving to give a better performance and higher productivity. For 
example formulations including inosine or deaza compounds helped to eliminate 
compression problems: and a new enzyme formulation, Perkin-Elmer AmpliTaq DNA 
Polymerase CS-I- should significantiy reduce false stops and drop out peaks encountered 
in Dye Primer Cycle Sequencing. It contains a single point mutation to eliminate the 
inherent 5'-3' nuclease activity, and a thermostable inorganic pyrophosphatase. 
Extended read lengths are being gained by the use of these further optimised chemistries, 
adapted autosequencers with longer well to read distances and improved computer base 
calhng algorithms. The capacity of machines can be increased by using the four dye 
technology and more channels per gel. The new ABI PRISM 377 DNA Sequencer 
incorporates many significant improvements including a more flexible sensitive 
simultaneous multicolour detection system using a CCD camera, longer thinner gels run 
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faster under actively controlled temperature conditions. It is perceived that major new 
developments will be made in this area or perhaps radical new methods such as capillary 
electrophoresis (CE), sequencing by hybridisation (SBH) to ohgonucleotides, multiplex 
sequencing or microscopic sequencing will be utilised (Jones, 1995). 
Either way within a year or two most large cDNA or genome sequencing institutions 
may resemble a factory with technology and robotics at the forefront generating data 
efficiently with reduced labour and costs. An automated laboratory produces over 10 
million DNA bases a year, with projected costs critically now at between 7 and 25 pence 
per base (Science, 1995). The biological strategies on which these energies are directed 
are critical to the continued success of the Human Genome Project: collaboration and 
co-ordination must continue. Informed decisions must be made by the relevant leading 
scientists regarding evolving strategies, and future issues such as ethics relating to 
personal genetic information and gene therapy as required. 
In conclusion it can be seen that in mans race to walk on the moon in the Human 
Genome Project and sequence the complete human genome, the spacecraft has been built 
and has taken o f f ESTs have been generated with the current technology and have been 
a biological breakthrough in gaining the correct co-ordinates of the destination; and will 
continue to do so, helping to map all genes. Further advances in technology should lead 
to a faster easier journey through less interesting space, the intron DNA, giving rapid 
genomic sequencing in the years to come so that the project is completed on time. On 
arrival the actual use of all this specific genetic information generated to gain a 
ubiquitous clinical advantage will be a large step for mankind. 
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6. APPENDIX 
Centrifugation data 
RCF = (rw')/g 
rpm = (1000)(V357/r) 
Beckman 50 Ti rotor max radius = 80.8 mm 
DNA conversion data 
Average molecular weight of a deoxynucleotide base = 324.5 Daltons 
1 A260 unit of double-stranded DNA = 50 \ig 
1 A260 unit of single-stranded DNA = 37 |jg 
1 A260 unit of single-stranded RNA = 40 jig 
Purity of RNA can be measured by A260/A280: a ratio of 1.8-2.0 is good 
(A26o= absorbance taken at 260 nanometres, A280 = absorbance taken at 280 
nanometres) 
DNA molecular weight marker V I (Boehringer Mannheim), pBR322 DNA Bgl I + 
pBR322 DNAHinfl, solution in 10 mM Tris-HCl, 1 mM EDTA, pH 8.0, 0.25 ng/^il 
Fragment sizes: 2176, 1766, 1230, 1033, 653, 517, 453, 394, 298, 234, 220, 154 base 
pairs 
DNA molecular weight marker I I I (Boehringer Mannheim), X DNAEcoR I + Hind IE, 
solution in 10 mM Tris-HCl, 1 mM EDTA, pH 8.0, 0.25 ^g/|il 
Fragment sizes: 21226, 5148, 4973, 4268, 3530, 2027, 1904, 1584, 1375, 947, 831, 564, 
125 base pairs 
PRISM™ Ready Reaction DyeDeoxy™ Terminator Cycle Sequencing Kit Premix: 
(1.58 ^ M A-DyeDeoxy, 94.74 ^iM T-DyeDeoxy, 0.42 ^iM G-DyeDeoxy, 47.37 | iM C-
DyeDeoxy, 78.95 | i M dITP, 15.79 MM dATP, 15.79 | i M dCTP, 15.79 |iiM dTTP, 
168.42 mM Tris-HCl (pH 9.0), 4.21 mM (NH4)2S04, 42.10 mM MgCl2, 0.42 units/^l 
AmpliTaq DNA polymerase) 
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160 mis of 6% acrylamide-urea gel solution 
80 g Urea 
24 mis 40% Acrylamide stock solution 
50 mis MilliQ water 
2 g mixed-bed, ion-exchange resin 
160 mis of 4.75% acrylamide-urea gel solution 
80 g Urea 
19 mis 40% Acrylamide stock solution 
47 mis MilliQ water 
2 g mixed-bed, ion-exchange resin 
0.2 ^m filtered and degassed for five minutes 
16 mis of f.s. lOxTBE (108 g Tris, 55.0 g Boric acid, 8.3 g EDTA, H2O to 1 Htre) 
Filter sterile MilliQ water to a final volume of 160 mis 
Polymerisation of 50 mis gel: 250 microlitres 10% ammonium persulphate (1 g/lOmls), 
and 25 microUtres TEMED 
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